{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "a4781b6c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: anthropic in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (0.68.0)\n",
      "Requirement already satisfied: distro<2,>=1.7.0 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from anthropic) (1.9.0)\n",
      "Requirement already satisfied: docstring-parser<1,>=0.15 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from anthropic) (0.17.0)\n",
      "Requirement already satisfied: sniffio in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from anthropic) (1.3.0)\n",
      "Requirement already satisfied: typing-extensions<5,>=4.10 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from anthropic) (4.13.2)\n",
      "Requirement already satisfied: pydantic<3,>=1.9.0 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from anthropic) (2.10.6)\n",
      "Requirement already satisfied: jiter<1,>=0.4.0 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from anthropic) (0.9.1)\n",
      "Requirement already satisfied: httpx<1,>=0.25.0 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from anthropic) (0.28.1)\n",
      "Requirement already satisfied: anyio<5,>=3.5.0 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from anthropic) (3.6.1)\n",
      "Requirement already satisfied: idna>=2.8 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from anyio<5,>=3.5.0->anthropic) (3.4)\n",
      "Requirement already satisfied: httpcore==1.* in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from httpx<1,>=0.25.0->anthropic) (1.0.9)\n",
      "Requirement already satisfied: certifi in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from httpx<1,>=0.25.0->anthropic) (2022.9.24)\n",
      "Requirement already satisfied: h11>=0.16 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from httpcore==1.*->httpx<1,>=0.25.0->anthropic) (0.16.0)\n",
      "Requirement already satisfied: annotated-types>=0.6.0 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from pydantic<3,>=1.9.0->anthropic) (0.7.0)\n",
      "Requirement already satisfied: pydantic-core==2.27.2 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from pydantic<3,>=1.9.0->anthropic) (2.27.2)\n",
      "Collecting openai\n",
      "  Downloading openai-1.109.1-py3-none-any.whl (948 kB)\n",
      "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m948.6/948.6 kB\u001b[0m \u001b[31m17.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0ma \u001b[36m0:00:01\u001b[0m\n",
      "\u001b[?25hRequirement already satisfied: httpx<1,>=0.23.0 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from openai) (0.28.1)\n",
      "Requirement already satisfied: sniffio in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from openai) (1.3.0)\n",
      "Requirement already satisfied: tqdm>4 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from openai) (4.64.1)\n",
      "Requirement already satisfied: anyio<5,>=3.5.0 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from openai) (3.6.1)\n",
      "Requirement already satisfied: jiter<1,>=0.4.0 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from openai) (0.9.1)\n",
      "Requirement already satisfied: typing-extensions<5,>=4.11 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from openai) (4.13.2)\n",
      "Requirement already satisfied: pydantic<3,>=1.9.0 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from openai) (2.10.6)\n",
      "Requirement already satisfied: distro<2,>=1.7.0 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from openai) (1.9.0)\n",
      "Requirement already satisfied: idna>=2.8 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from anyio<5,>=3.5.0->openai) (3.4)\n",
      "Requirement already satisfied: certifi in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from httpx<1,>=0.23.0->openai) (2022.9.24)\n",
      "Requirement already satisfied: httpcore==1.* in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from httpx<1,>=0.23.0->openai) (1.0.9)\n",
      "Requirement already satisfied: h11>=0.16 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from httpcore==1.*->httpx<1,>=0.23.0->openai) (0.16.0)\n",
      "Requirement already satisfied: pydantic-core==2.27.2 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from pydantic<3,>=1.9.0->openai) (2.27.2)\n",
      "Requirement already satisfied: annotated-types>=0.6.0 in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from pydantic<3,>=1.9.0->openai) (0.7.0)\n",
      "Installing collected packages: openai\n",
      "Successfully installed openai-1.109.1\n"
     ]
    }
   ],
   "source": [
    "!pip install anthropic\n",
    "!pip install openai\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "efa25fc3",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: openpyxl in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (3.1.5)\n",
      "Requirement already satisfied: et-xmlfile in /Users/lindazhou/opt/anaconda3/envs/myenv/lib/python3.8/site-packages (from openpyxl) (2.0.0)\n"
     ]
    }
   ],
   "source": [
    "!pip install openpyxl"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "ccb26974",
   "metadata": {},
   "outputs": [],
   "source": [
    "from pathlib import Path\n",
    "import pandas as pd\n",
    "from openai import OpenAI\n",
    "import re\n",
    "\n",
    "\n",
    "client = OpenAI(api_key=openai_api_key)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "07e96751",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "def complete_with_continuation(prompt, model=\"gpt-5-nano\", save_path = \"\", max_tokens=4096):\n",
    "    messages = [{\"role\": \"user\", \"content\": prompt}]\n",
    "    full_output = \"\"\n",
    "    total_input_tokens = 0\n",
    "    total_cached_tokens = 0\n",
    "    total_output_tokens = 0\n",
    "\n",
    "    while True:\n",
    "        response = client.chat.completions.create(\n",
    "            model=model,\n",
    "            # max_tokens=max_tokens,\n",
    "            messages=messages\n",
    "        )\n",
    "\n",
    "        choice = response.choices[0]\n",
    "        content = choice.message.content   # ✅ fixed\n",
    "        finish_reason = choice.finish_reason\n",
    "\n",
    "        # Add the new output to the full string\n",
    "        full_output += content\n",
    "\n",
    "        # --- Token + cost tracking ---\n",
    "        usage = response.usage\n",
    "        input_tokens = usage.prompt_tokens\n",
    "        cached_input_tokens = getattr(usage, \"cached_prompt_tokens\", 0)  # safe fallback\n",
    "        output_tokens = usage.completion_tokens\n",
    "        total_tokens = usage.total_tokens\n",
    "\n",
    "        # Accumulate totals\n",
    "        total_input_tokens += input_tokens\n",
    "        total_cached_tokens += cached_input_tokens\n",
    "        total_output_tokens += output_tokens\n",
    "\n",
    "        # print(f\"\\n--- API Call Usage ---\")\n",
    "        # print(f\"Input tokens: {input_tokens}\")\n",
    "        # print(f\"Cached input tokens: {cached_input_tokens}\")\n",
    "        # print(f\"Output tokens: {output_tokens}\")\n",
    "        # print(f\"Total tokens: {total_tokens}\")\n",
    "\n",
    "        # Cost for this call\n",
    "        input_cost = input_tokens * (0.05 / 1_000_000)\n",
    "        cached_input_cost = cached_input_tokens * (0.005 / 1_000_000)\n",
    "        output_cost = output_tokens * (0.40 / 1_000_000)\n",
    "        call_cost = input_cost + cached_input_cost + output_cost\n",
    "        # print(f\"Estimated cost (this call): ${call_cost:.6f}\")\n",
    "\n",
    "        if finish_reason == \"length\":\n",
    "            # Truncated — add a continuation message\n",
    "            messages.append({\"role\": \"assistant\", \"content\": content})\n",
    "            messages.append({\"role\": \"user\", \"content\": \"Continue where you left off.\"})\n",
    "        else:\n",
    "            break\n",
    "\n",
    "    # --- Final total cost ---\n",
    "    total_cost = (\n",
    "        total_input_tokens * (0.05 / 1_000_000)\n",
    "        + total_cached_tokens * (0.005 / 1_000_000)\n",
    "        + total_output_tokens * (0.40 / 1_000_000)\n",
    "    )\n",
    "\n",
    "    # print(f\"\\n=== Total Usage Across All Calls ===\")\n",
    "    # print(f\"Input tokens: {total_input_tokens}\")\n",
    "    # print(f\"Cached input tokens: {total_cached_tokens}\")\n",
    "    # print(f\"Output tokens: {total_output_tokens}\")\n",
    "    # print(f\"Grand total tokens: {total_input_tokens + total_cached_tokens + total_output_tokens}\")\n",
    "    # print(f\"Estimated total cost: ${total_cost:.6f}\")\n",
    "    # Prepare a dictionary with the info\n",
    "    usage_data = {\n",
    "        \"Metric\": [\n",
    "            \"Input tokens\",\n",
    "            \"Cached input tokens\",\n",
    "            \"Output tokens\",\n",
    "            \"Grand total tokens\",\n",
    "            \"Estimated total cost\"\n",
    "        ],\n",
    "        \"Value\": [\n",
    "            total_input_tokens,\n",
    "            total_cached_tokens,\n",
    "            total_output_tokens,\n",
    "            total_input_tokens + total_cached_tokens + total_output_tokens,\n",
    "            total_cost\n",
    "        ]\n",
    "    }\n",
    "\n",
    "    # Create a DataFrame\n",
    "    df_usage = pd.DataFrame(usage_data)\n",
    "\n",
    "    # Ensure parent directories exist\n",
    "    save_path.parent.mkdir(parents=True, exist_ok=True)\n",
    "\n",
    "    # Save to Excel\n",
    "    df_usage.to_excel(save_path, index=False)\n",
    "\n",
    "    return full_output\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "6ce58e71",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1101: Does the paper report previously unpublished data?\n",
      "1102: Does the paper report HIV sequences?\n",
      "1103: Does the paper report the results of in vitro passage experiments?\n",
      "1104: Does the paper report in vitro antiretroviral susceptibility data?\n",
      "2101: Does the paper report GenBank accession numbers for sequenced HIV isolates?\n",
      "2102: Does the paper report GenBank accession numbers for sequenced HIV isolates other than those for laboratory HIV isolates?\n",
      "2103: Which are the genbank accession numbers reported in the paper?\n",
      "2202: Does the paper report lists of mutations for individual sequenced HIV isolates?\n",
      "2301: Which HIV species were studied in the paper?\n",
      "2302: What were the subtypes of the sequenced viruses reported in the paper?\n",
      "2303: Which HIV genes were sequenced in the paper?\n",
      "2304: Does the paper report the results of HIV pol sequences?\n",
      "2401: Which geographic regions and/or countries were the sequences from in the paper?\n",
      "2402: What years were the sequenced samples obtained in the paper?\n",
      "2502: Was sequencing in the paper performed using Sanger sequencing?\n",
      "2503: Was sequencing in the paper performed using an NGS technology?\n",
      "2504: Were samples in the paper cloned prior to sequencing?\n",
      "2505: Did the samples in the paper undergo single genome sequencing?\n",
      "2506: Did the samples in the paper undergo molecular cloning?\n",
      "2601: Does the paper report the results of plasma HIV sequencing?\n",
      "2602: Does the paper report the results of PBMC HIV sequencing?\n",
      "2603: How many samples in the paper were reported to have undergone plasma virus sequencing?\n",
      "2604: How many samples in the paper were reported to have undergone PBMC virus sequencing?\n",
      "2605: Were sequences in the paper obtained from individuals with active HIV replication?\n",
      "2606: Were sequences in the paper obtained from the proviral DNA reservoir?\n",
      "2701: Does the paper report samples obtain from infants and/or children?\n",
      "2702: Were any of the individuals in the paper in a clinical trial?\n",
      "2703: Were all of the individuals in the paper in a clinical trial?\n",
      "3101: IHow many individuals in the paper had samples obtained for HIV sequencing?\n",
      "3102: Did all of the individuals in the paper undergo HIV sequencing?\n",
      "4101: Does the paper report HIV sequences from individuals who were ART-naive?\n",
      "4102: Does the paper report HIV sequences from individuals who had previously received ARV drugs?\n",
      "4103: Does the paper report HIV sequences from individuals who were ART-naive and from persons who were ART-experienced?\n",
      "4104: How many samples in the paper were obtained from ART-naive individuals?\n",
      "4105: Does the paper provide complete ART history information for all of the individuals in the study?\n",
      "4201: Does the paper report information on the prevalence of transmitted HIV drug resistance?\n",
      "4202: Does the paper report information on the prevalence of pretreatment HIV drug resistance?\n",
      "4301: Which drug classes were received by individuals in the paper?\n",
      "4302: Does the paper report information on individuals who received integrase inhibitors?\n",
      "4303: Does the paper report information on individuals who received protease inhibitors?\n",
      "4304: Did all of the individuals in the paper receive the same ART?\n",
      "4305: Were the individuals in the paper INSTI-naive?\n",
      "4403: How many individuals in the paper received more than one ART regimen?\n",
      "4404: How many individuals in the paper received more than two ART regimens?\n",
      "4405: Did all individuals in the paper receive the same number of ART regimens?\n",
      "4406: Did all individuals in the paper receive one ART regimen?\n",
      "4501: How many individuals in the paper received dolutegravir?\n",
      "4502: How many individuals in the paper received darunavir?\n",
      "5101: How many individuals in the paper were found to have one or more drug resistance mutation?\n",
      "5102: How many individuals in the paper were found to have INSTI-resistance mutations?\n",
      "5103: How many individuals in the paper were found to have TDF-resistance mutations?\n",
      "5104: Which INSTI-resistance mutations were reported to have developed in individuals in the paper?\n",
      "6101: What method in the paper was used on phenotypic susceptibility test?\n",
      "6102: Does the paper report IC values like IC50? IC90?\n",
      "6103: Does the paper report IC50 fold change values?\n",
      "6104: Which phenotypic susceptibility assay was used in the paper?\n",
      "6105: Dose the paper report data about replication capacity?\n",
      "6106: Which drugs were tested on phenotypic susceptibility in the paper?\n",
      "7101: Were any of the isolates described in the paper site-directed mutations?\n",
      "7102: Did any of the isolates in the paper result from in vitro passage experiments?\n"
     ]
    }
   ],
   "source": [
    "\n",
    "    \n",
    "# 60 questions\n",
    "# read the Excel file, first sheet\n",
    "df_60 = pd.read_excel(\"60questions.xlsx\", sheet_name=0)\n",
    "\n",
    "# get all id and question column questions in a list, id followed by question\n",
    "# \n",
    "# make list into \\n separated, str \n",
    "\n",
    "combined_list = df_60.apply(lambda row: f\"{row['id']}: {row['question']}\", axis=1).tolist()\n",
    "\n",
    "# Join into one string with newline separators\n",
    "questions_block = \"\\n\".join(combined_list)\n",
    "\n",
    "print(questions_block)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "0918ad93",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Skipping Yao2015, 25410050, output file already exists.\n",
      "\"\"\"\n",
      "Question: 1101 \n",
      "\n",
      "Evidence: A cross-sectional study design was used to study the DR profiles in LLV patients who were followed up in Jiangsu Province in 2021. In this study, a total of 345 samples were collected throughout 2021.\n",
      "\n",
      "Rationale: The paper describes a new cross-sectional investigation conducted in 2021 with newly collected samples and analyses, indicating that it reports previously unpublished data from this cohort.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 1102 \n",
      "\n",
      "Evidence: After nucleic acid extraction, PCR amplification and sequencing were performed on the plasma of 345 samples, Pol genes of 255 patients were obtained. Thirteen cases of sequences with poor quality or unmatched information were removed, and 242 cases of sequences meeting the research requirements were finally included.\n",
      "\n",
      "Rationale: The text explicitly states that HIV pol genes were amplified and sequenced from patient plasma, confirming that the study reports HIV sequences.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 1103 \n",
      "\n",
      "Evidence: A cross-sectional study design was used to study the DR profiles in LLV patients who were followed up in Jiangsu Province in 2021. After nucleic acid extraction, PCR amplification and sequencing were performed on the plasma of 345 samples.\n",
      "\n",
      "Rationale: The methods describe clinical sample sequencing and analysis; there is no mention of culturing virus or conducting in vitro passage experiments, indicating such experiments were not performed.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 1104 \n",
      "\n",
      "Evidence: Pol region sequences were uploaded to the HIV Drug Resistance Database (https://hivdb.Stanford.edu/) for drug resistance analysis. The drug resistance degree of each drug was divided into five grades.\n",
      "\n",
      "Rationale: The study conducted genotypic resistance interpretation using the Stanford HIVDB algorithm and did not perform phenotypic susceptibility testing (no assays, IC values, or fold-changes reported), so there is no in vitro susceptibility data.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2101 \n",
      "\n",
      "Evidence: ChromasPro (Version: 1.6) was used for sequence spliced, website (https://comet.Lih.lu/) and HIV database (https://www.hiv.lanl.gov/content/sequence/BASIC_BLAST/basic_blast.html) were used for subtype determination. Pol region sequences were uploaded to the HIV Drug Resistance Database (https://hivdb.Stanford.edu/) for drug resistance analysis.\n",
      "\n",
      "Rationale: The paper describes sequence processing and external databases used for analysis but does not provide any GenBank accession numbers, indicating none were reported.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2102 \n",
      "\n",
      "Evidence: ChromasPro (Version: 1.6) was used for sequence spliced, website (https://comet.Lih.lu/) and HIV database (https://www.hiv.lanl.gov/content/sequence/BASIC_BLAST/basic_blast.html) were used for subtype determination. Pol region sequences were uploaded to the HIV Drug Resistance Database (https://hivdb.Stanford.edu/) for drug resistance analysis.\n",
      "\n",
      "Rationale: No GenBank accession numbers of any kind (including for non-laboratory clinical isolates) are provided in the text.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2103 \n",
      "\n",
      "Evidence: ChromasPro (Version: 1.6) was used for sequence spliced, website (https://comet.Lih.lu/) and HIV database (https://www.hiv.lanl.gov/content/sequence/BASIC_BLAST/basic_blast.html) were used for subtype determination. Pol region sequences were uploaded to the HIV Drug Resistance Database (https://hivdb.Stanford.edu/) for drug resistance analysis.\n",
      "\n",
      "Rationale: The manuscript does not list any GenBank accession numbers; therefore, specific accession numbers cannot be provided.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2202 \n",
      "\n",
      "Evidence: The DRM sites and corresponding drug sensitivity of 98 patients with drug resistance are shown in the Supplementary Materials. Sixty-six of the 98 patients had NRTIs-related DRM sites, and all caused low or above level drug resistance.\n",
      "\n",
      "Rationale: The paper states that per-patient DRM sites and corresponding sensitivities are presented in the supplementary materials, implying lists of mutations for individual sequenced isolates.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2301 \n",
      "\n",
      "Evidence: HIV-1 Drug Resistance Profiles of Low-Level Viremia Patients and Factors Associated With the Treatment Effect of ART-Treated Patients: A Cross-Sectional Study in Jiangsu, China. Ten HIV-1 genotypes were detected based on the Pol gene fragments from 242 cases.\n",
      "\n",
      "Rationale: The title and results explicitly reference HIV-1, indicating the species studied is HIV-1.\n",
      "\n",
      "Answer: HIV-1\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2302 \n",
      "\n",
      "Evidence: Ten HIV-1 genotypes were detected based on the Pol gene fragments from 242 cases. A total of 10 HIV-1 genotypes were detected, the proportion from high to low were as follows: CRF01_AE, CRF07_BC, B, CRF67_01B, CRF08_BC, CRF55_01B, CRF68_01B, 01BC, 0107 and CRF65_cpx.\n",
      "\n",
      "Rationale: The paper lists the detected genotypes/subtypes directly, including multiple CRFs, subtype B, and URFs.\n",
      "\n",
      "Answer: CRF01_AE, CRF07_BC, subtype B, CRF67_01B, CRF08_BC, CRF55_01B, CRF68_01B, 01BC (URF), 0107 (URF), CRF65_cpx\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2303 \n",
      "\n",
      "Evidence: Target genes in the Pol region (Reverse transcriptase and protease) were amplified by the in-house method. Pol region sequences were uploaded to the HIV Drug Resistance Database (https://hivdb.Stanford.edu/) for drug resistance analysis.\n",
      "\n",
      "Rationale: The methods specify amplification and sequencing of the pol region, specifically reverse transcriptase and protease.\n",
      "\n",
      "Answer: pol (reverse transcriptase and protease)\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2304 \n",
      "\n",
      "Evidence: Target genes in the Pol region (Reverse transcriptase and protease) were amplified by the in-house method. Pol region sequences were uploaded to the HIV Drug Resistance Database (https://hivdb.Stanford.edu/) for drug resistance analysis.\n",
      "\n",
      "Rationale: The study generated and analyzed pol sequences, thus reporting results of HIV pol sequences.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2401 \n",
      "\n",
      "Evidence: A cross-sectional study design was used to study the DR profiles in LLV patients who were followed up in Jiangsu Province in 2021. The samples of this study were collected by the drug resistance monitoring program for HIV/AIDS patients in Jiangsu Province.\n",
      "\n",
      "Rationale: The sampling location is Jiangsu Province, China; all sequences originate from this geographic region.\n",
      "\n",
      "Answer: Jiangsu Province, China\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2402 \n",
      "\n",
      "Evidence: A cross-sectional study design was used to study the DR profiles in LLV patients who were followed up in Jiangsu Province in 2021. In this study, a total of 345 samples were collected throughout 2021.\n",
      "\n",
      "Rationale: The text clearly states the year of follow-up and sample collection.\n",
      "\n",
      "Answer: 2021\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2502 \n",
      "\n",
      "Evidence: PCR products were sent to Sangon Biotech for sequencing. ChromasPro (Version: 1.6) was used for sequence spliced.\n",
      "\n",
      "Rationale: Sending PCR products for sequencing and using ChromasPro (a Sanger chromatogram editor) indicates Sanger sequencing was used.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2503 \n",
      "\n",
      "Evidence: PCR amplification and sequencing were performed on the plasma of 345 samples. PCR products were sent to Sangon Biotech for sequencing.\n",
      "\n",
      "Rationale: The methods describe RT-PCR/nested PCR followed by standard sequencing, without any mention of next-generation sequencing platforms or methods.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2504 \n",
      "\n",
      "Evidence: PCR products were sent to Sangon Biotech for sequencing. Target genes in the Pol region (Reverse transcriptase and protease) were amplified by the in-house method.\n",
      "\n",
      "Rationale: The paper does not mention cloning of samples prior to sequencing; without explicit information, this cannot be determined.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2505 \n",
      "\n",
      "Evidence: PCR products were sent to Sangon Biotech for sequencing. ChromasPro (Version: 1.6) was used for sequence spliced.\n",
      "\n",
      "Rationale: The study describes bulk PCR and standard sequencing workflows; single-genome sequencing is not mentioned.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2506 \n",
      "\n",
      "Evidence: Target genes in the Pol region (Reverse transcriptase and protease) were amplified by the in-house method. PCR products were sent to Sangon Biotech for sequencing.\n",
      "\n",
      "Rationale: There is no description of molecular cloning of viral genomes; without explicit detail, this cannot be determined.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2601 \n",
      "\n",
      "Evidence: After nucleic acid extraction, PCR amplification and sequencing were performed on the plasma of 345 samples. Pol genes of 255 patients were obtained.\n",
      "\n",
      "Rationale: The paper explicitly states sequencing was performed on plasma samples.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2602 \n",
      "\n",
      "Evidence: PCR amplification and sequencing were performed on the plasma of 345 samples. The samples of this study were collected by the drug resistance monitoring program for HIV/AIDS patients in Jiangsu Province.\n",
      "\n",
      "Rationale: The sequencing source is specified as plasma; PBMC sequencing is not mentioned anywhere, indicating no PBMC sequencing results were reported.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2603 \n",
      "\n",
      "Evidence: After nucleic acid extraction, PCR amplification and sequencing were performed on the plasma of 345 samples. Pol genes of 255 patients were obtained.\n",
      "\n",
      "Rationale: The text states that sequencing was performed on the plasma of 345 samples; although only a subset yielded analyzable sequences, 345 samples underwent plasma sequencing attempts.\n",
      "\n",
      "Answer: 345\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2604 \n",
      "\n",
      "Evidence: After nucleic acid extraction, PCR amplification and sequencing were performed on the plasma of 345 samples. There is no mention of PBMC sequencing in the methods or results.\n",
      "\n",
      "Rationale: Only plasma sequencing is described; therefore, the number of PBMC virus sequences is zero.\n",
      "\n",
      "Answer: 0\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2605 \n",
      "\n",
      "Evidence: Inclusion criteria included: VL was in the range of 50–1,000 copies/ml during follow-up. After nucleic acid extraction, PCR amplification and sequencing were performed on the plasma of 345 samples.\n",
      "\n",
      "Rationale: Detectable plasma viral load (50–1,000 copies/mL) indicates ongoing viremia, i.e., active replication, from which sequences were obtained.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2606 \n",
      "\n",
      "Evidence: Target genes in the Pol region (Reverse transcriptase and protease) were amplified by the in-house method. After nucleic acid extraction, PCR amplification and sequencing were performed on the plasma of 345 samples.\n",
      "\n",
      "Rationale: The sequencing used RT-PCR on plasma RNA rather than proviral DNA from cells, so sequences were not obtained from the proviral DNA reservoir.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2701 \n",
      "\n",
      "Evidence: Inclusion criteria included: The subjects were older than 18 years at follow-up. Inclusion criteria were: age 18 and above.\n",
      "\n",
      "Rationale: Only adults were included; no infants or children.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2702 \n",
      "\n",
      "Evidence: A cross-sectional study design was used to study the DR profiles in LLV patients who were followed up in Jiangsu Province in 2021. The samples of this study were collected by the drug resistance monitoring program for HIV/AIDS patients in Jiangsu Province.\n",
      "\n",
      "Rationale: The study is observational within a provincial monitoring program, not a clinical trial; no trial participation is mentioned.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2703 \n",
      "\n",
      "Evidence: A cross-sectional study design was used to study the DR profiles in LLV patients who were followed up in Jiangsu Province in 2021. The samples of this study were collected by the drug resistance monitoring program for HIV/AIDS patients in Jiangsu Province.\n",
      "\n",
      "Rationale: Since it was not a clinical trial, it is not the case that all individuals were in a clinical trial.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 3101 \n",
      "\n",
      "Evidence: In this study, a total of 345 samples were collected throughout 2021. After nucleic acid extraction, PCR amplification and sequencing were performed on the plasma of 345 samples.\n",
      "\n",
      "Rationale: The number of individuals with samples obtained for sequencing corresponds to the 345 collected and sequenced plasma samples.\n",
      "\n",
      "Answer: 345\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 3102 \n",
      "\n",
      "Evidence: Pol genes of 255 patients were obtained. Thirteen cases of sequences with poor quality or unmatched information were removed, and 242 cases of sequences meeting the research requirements were finally included.\n",
      "\n",
      "Rationale: Not all sampled individuals yielded usable sequences; therefore, not all individuals underwent successful HIV sequencing.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4101 \n",
      "\n",
      "Evidence: Inclusion criteria included: ART time at follow-up was more than 6 months. Inclusion criteria included: VL was in the range of 50–1,000 copies/ml during follow-up.\n",
      "\n",
      "Rationale: All participants were on ART for over 6 months; there were no ART-naive individuals.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4102 \n",
      "\n",
      "Evidence: Inclusion criteria included: ART time at follow-up was more than 6 months. The majority of patients received 2NRTIs+NNRTIs at follow-up, followed by 2NRTIs+PIs.\n",
      "\n",
      "Rationale: Participants were ART-experienced with specified ongoing regimens.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4103 \n",
      "\n",
      "Evidence: Inclusion criteria included: ART time at follow-up was more than 6 months. Patients in the case group were 50–1,000 copies/ml, while patients in the control group were VS patients.\n",
      "\n",
      "Rationale: All participants were ART-experienced; there were no ART-naive subjects, so the study does not include both naive and experienced groups.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4104 \n",
      "\n",
      "Evidence: Inclusion criteria included: ART time at follow-up was more than 6 months. The follow-up period was from January 2021 to December 2021.\n",
      "\n",
      "Rationale: Because ART for more than 6 months was required, there were no ART-naive samples.\n",
      "\n",
      "Answer: 0\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4105 \n",
      "\n",
      "Evidence: The majority of patients received 2NRTIs+NNRTIs at follow-up, followed by 2NRTIs+PIs. Treatment duration was more than half a year (≥180 days) at the time of follow-up.\n",
      "\n",
      "Rationale: The paper reports current regimen categories and general durations but does not provide comprehensive, individual-level ART histories for all participants.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4201 \n",
      "\n",
      "Evidence: A cross-sectional study design was used to study the DR profiles in LLV patients who were followed up in Jiangsu Province in 2021. Inclusion criteria included: ART time at follow-up was more than 6 months.\n",
      "\n",
      "Rationale: The study involves ART-experienced patients with LLV/VS at follow-up; it does not assess transmitted (baseline pretreatment) resistance prevalence.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4202 \n",
      "\n",
      "Evidence: Inclusion criteria included: ART time at follow-up was more than 6 months. Patients in the control group were VS patients (VL<50 copies/ml).\n",
      "\n",
      "Rationale: The study did not enroll ART-naive individuals for pretreatment resistance assessment; hence, it does not report pretreatment resistance prevalence.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4301 \n",
      "\n",
      "Evidence: The treatment regimens were divided into four categories. Patients using the 2NRTIs+NNRTIs regimen accounted for the highest proportion, followed by 2NRTIs+PIs, and 2NRTIs+INSTIs.\n",
      "\n",
      "Rationale: These categories indicate that individuals received NRTIs with NNRTIs, PIs, or INSTIs.\n",
      "\n",
      "Answer: NRTIs, NNRTIs, PIs, INSTIs\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4302 \n",
      "\n",
      "Evidence: The treatment regimens were divided into four categories. 2NRTIs+INSTIs was one of the reported categories and was used by some patients.\n",
      "\n",
      "Rationale: The presence of a 2NRTIs+INSTIs group shows that some individuals received integrase inhibitors.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4303 \n",
      "\n",
      "Evidence: The treatment regimens were divided into four categories. Patients using the 2NRTIs+PIs regimen accounted for 28.6% among drug-resistant patients and were also present in the questionnaire cohort.\n",
      "\n",
      "Rationale: The reported regimens include protease inhibitor–based therapy.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4304 \n",
      "\n",
      "Evidence: The treatment regimens were divided into four categories. The majority of patients received 2NRTIs+NNRTIs at follow-up, followed by 2NRTIs+PIs and 2NRTIs+INSTIs.\n",
      "\n",
      "Rationale: Multiple different regimen types were used, so not all individuals received the same ART.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4305 \n",
      "\n",
      "Evidence: 2NRTIs+INSTIs was one of the treatment regimens reported. At follow-up, 10 patients in the VS group and 7 patients in the LLV group received 2NRTIs+INSTIs.\n",
      "\n",
      "Rationale: Because some individuals were on INSTI-containing regimens, not all participants were INSTI-naive.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4403 \n",
      "\n",
      "Evidence: The treatment regimens were divided into four categories. The majority of patients received 2NRTIs+NNRTIs at follow-up, followed by 2NRTIs+PIs and 2NRTIs+INSTIs.\n",
      "\n",
      "Rationale: The paper reports regimen categories at follow-up but does not state how many individuals had more than one regimen over time; thus this cannot be determined.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4404 \n",
      "\n",
      "Evidence: The treatment regimens were divided into four categories. The majority of patients received 2NRTIs+NNRTIs at follow-up, followed by 2NRTIs+PIs and 2NRTIs+INSTIs.\n",
      "\n",
      "Rationale: There is no information on the count of individuals receiving more than two regimens.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4405 \n",
      "\n",
      "Evidence: The treatment regimens were divided into four categories. The majority of patients received 2NRTIs+NNRTIs at follow-up, followed by 2NRTIs+PIs and 2NRTIs+INSTIs.\n",
      "\n",
      "Rationale: The study does not report the number of regimens per individual; therefore, whether all received the same number cannot be determined.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4406 \n",
      "\n",
      "Evidence: The treatment regimens were divided into four categories. The majority of patients received 2NRTIs+NNRTIs at follow-up, followed by 2NRTIs+PIs and 2NRTIs+INSTIs.\n",
      "\n",
      "Rationale: The paper does not specify whether each individual received only one regimen; this is not determinable from the provided information.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4501 \n",
      "\n",
      "Evidence: The treatment regimens were divided into four categories. 2NRTIs+INSTIs regimens were reported but specific INSTI drugs were not listed.\n",
      "\n",
      "Rationale: Specific INSTI agents such as dolutegravir are not enumerated; hence the number of individuals on dolutegravir cannot be determined.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4502 \n",
      "\n",
      "Evidence: The treatment regimens were divided into four categories. 2NRTIs+PIs regimens were reported but specific PI drugs taken by individuals were not listed.\n",
      "\n",
      "Rationale: Although PI resistance to various drugs was analyzed genotypically, the actual PI drugs received (e.g., darunavir) are not specified for individuals; thus, counts cannot be provided.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 5101 \n",
      "\n",
      "Evidence: There are 98 drug resistance sequences among 242 pol genes (low or above level resistance to any class of drugs). According to the drug resistance analysis results, 66 drug resistance mutation (DRM) sites were detected in 98 patients with drug resistance.\n",
      "\n",
      "Rationale: The text states that 98 patients had sequences showing drug resistance (and DRMs), which corresponds to individuals with one or more DRMs.\n",
      "\n",
      "Answer: 98\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 5102 \n",
      "\n",
      "Evidence: Target genes in the Pol region (Reverse transcriptase and protease) were amplified by the in-house method. Fifty-four DRM sites were detected in the reverse transcription (RT) region and 12 DRM sites in the protease inhibitors (PIs) region.\n",
      "\n",
      "Rationale: The integrase gene was not sequenced; therefore, no INSTI-resistance mutations could be detected or reported.\n",
      "\n",
      "Answer: 0\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 5103 \n",
      "\n",
      "Evidence: TDF appears in the NRTIs list in Table 4 with counts per regimen category. TDF shows a total of 23 resistant cases.\n",
      "\n",
      "Rationale: Table 4 summarizes the number of patients with resistance to specific drugs; for tenofovir (TDF), there are 23 cases.\n",
      "\n",
      "Answer: 23\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 5104 \n",
      "\n",
      "Evidence: Target genes in the Pol region (Reverse transcriptase and protease) were amplified by the in-house method. The DRM sites detected were in RT and PI regions; integrase inhibitor resistance mutations are not reported.\n",
      "\n",
      "Rationale: As integrase was not sequenced, the study did not report any INSTI-resistance mutations.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 6101 \n",
      "\n",
      "Evidence: Pol region sequences were uploaded to the HIV Drug Resistance Database (https://hivdb.Stanford.edu/) for drug resistance analysis. The drug resistance degree of each drug was divided into five grades.\n",
      "\n",
      "Rationale: The study used genotypic interpretation and did not perform phenotypic susceptibility testing; therefore, no phenotypic method is reported.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 6102 \n",
      "\n",
      "Evidence: Pol region sequences were uploaded to the HIV Drug Resistance Database (https://hivdb.Stanford.edu/) for drug resistance analysis. The drug resistance degree of each drug was divided into five grades.\n",
      "\n",
      "Rationale: No inhibitory concentration (IC50/IC90) values are presented; only genotypic resistance levels are reported.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 6103 \n",
      "\n",
      "Evidence: Pol region sequences were uploaded to the HIV Drug Resistance Database (https://hivdb.Stanford.edu/) for drug resistance analysis. The drug resistance degree of each drug was divided into five grades.\n",
      "\n",
      "Rationale: There are no fold-change IC50 values or phenotypic fold reductions reported.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 6104 \n",
      "\n",
      "Evidence: Pol region sequences were uploaded to the HIV Drug Resistance Database (https://hivdb.Stanford.edu/) for drug resistance analysis. The drug resistance degree of each drug was divided into five grades.\n",
      "\n",
      "Rationale: No phenotypic susceptibility assay is described; the analysis is purely genotypic.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 6105 \n",
      "\n",
      "Evidence: Pol region sequences were uploaded to the HIV Drug Resistance Database (https://hivdb.Stanford.edu/) for drug resistance analysis. The drug resistance degree of each drug was divided into five grades.\n",
      "\n",
      "Rationale: Replication capacity measurements are not mentioned anywhere in the paper.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 6106 \n",
      "\n",
      "Evidence: Pol region sequences were uploaded to the HIV Drug Resistance Database (https://hivdb.Stanford.edu/) for drug resistance analysis. The drug resistance degree of each drug was divided into five grades.\n",
      "\n",
      "Rationale: The paper does not report phenotypic susceptibility testing to specific drugs; only genotypic resistance interpretations are provided.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 7101 \n",
      "\n",
      "Evidence: After nucleic acid extraction, PCR amplification and sequencing were performed on the plasma of 345 samples. PCR products were sent to Sangon Biotech for sequencing.\n",
      "\n",
      "Rationale: The study examines clinical sequences from patient plasma and does not involve constructing site-directed mutant viruses.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 7102 \n",
      "\n",
      "Evidence: A cross-sectional study design was used to study the DR profiles in LLV patients who were followed up in Jiangsu Province in 2021. After nucleic acid extraction, PCR amplification and sequencing were performed on the plasma of 345 samples.\n",
      "\n",
      "Rationale: The methods do not include in vitro passaging; the data arise from direct clinical samples.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\"\"\"\n",
      "Question: 1101 \n",
      "\n",
      "Evidence: Patients with PLLV were retrospectively selected from the cohort of HIV-1-infected patients followed at the Ghent University Hospital. For the 28 selected PLLV patients a total of 590 VL measurements were performed during routine patient monitoring between initiation of ART and study closure. PR-RT amplification and sequencing was successful for 154 of the 378 samples.\n",
      "\n",
      "Rationale: The study describes original patient selection, measurements, and sequencing results from a specific hospital cohort, indicating that it reports newly generated clinical and sequencing data rather than summarizing previously published datasets.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 1102 \n",
      "\n",
      "Evidence: PR-RT amplification and sequencing was successful for 154 of the 378 samples. Sequencing was performed on the ABI3130 Sequencer (Applied Biosystems, Foster City, CA, USA) and sequences were analysed using SmartGene (IDNS™) software.\n",
      "\n",
      "Rationale: The methods and results explicitly state that HIV genomic regions (PR-RT) were amplified and sequenced, confirming that the paper reports HIV sequences.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 1103 \n",
      "\n",
      "Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol. An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples collected retrospectively between 6 months post-ART initiation and January 2013 and all samples collected until study closure (February 2014).\n",
      "\n",
      "Rationale: The study analyzes clinical plasma samples from patients rather than viruses passaged in cell culture; there is no description of serial in vitro passage experiments.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 1104 \n",
      "\n",
      "Evidence: DRM were defined as mutations with a score >10 according to the Stanford HIV Drug Resistance Database. Sequencing was performed on the ABI3130 Sequencer (Applied Biosystems, Foster City, CA, USA) and sequences were analysed using SmartGene (IDNS™) software.\n",
      "\n",
      "Rationale: The paper conducts genotypic resistance testing and interpretation without describing any phenotypic antiretroviral susceptibility assays.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2101 \n",
      "\n",
      "Evidence: Sequencing was performed on the ABI3130 Sequencer (Applied Biosystems, Foster City, CA, USA) and sequences were analysed using SmartGene (IDNS™) software. A maximum likelihood phylogenetic tree was constructed of all collected sequences.\n",
      "\n",
      "Rationale: Although sequences were generated and analyzed, the text does not provide any GenBank accession numbers for these sequences.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2102 \n",
      "\n",
      "Evidence: Sequencing was performed on the ABI3130 Sequencer (Applied Biosystems, Foster City, CA, USA) and sequences were analysed using SmartGene (IDNS™) software. A maximum likelihood phylogenetic tree was constructed of all collected sequences.\n",
      "\n",
      "Rationale: The paper does not list any GenBank accession numbers for clinical isolates (or any isolates), so none are reported for non-laboratory isolates.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2103 \n",
      "\n",
      "Evidence: Sequencing was performed on the ABI3130 Sequencer (Applied Biosystems, Foster City, CA, USA) and sequences were analysed using SmartGene (IDNS™) software. A maximum likelihood phylogenetic tree was constructed of all collected sequences.\n",
      "\n",
      "Rationale: The paper does not include any GenBank accession numbers; therefore, none can be listed.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2202 \n",
      "\n",
      "Evidence: Historical DRMs, detected before study initiation, were observed in three patients. Patient 13 was infected with an NRTI-resistant strain (mutations D67N, T69D and T215C) and this variant was consistently found in the five samples genotyped during PLLV. New DRM, not present at study initiation or in earlier samples, were found in four isolated samples from four different patients: K101E in patient 1, Y188C in patient 13, I50L in patient 19 and K219E in patient 21.\n",
      "\n",
      "Rationale: The paper specifies mutations detected for individual patients, effectively providing per-isolate (per-patient, per-sample) mutation lists.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2301 \n",
      "\n",
      "Evidence: Drug resistance is rarely the cause or consequence of long-term persistent low-level viraemia in HIV-1-infected patients on ART. Patients with PLLV were retrospectively selected from the cohort of HIV-1-infected patients followed at the Ghent University Hospital.\n",
      "\n",
      "Rationale: The title and methods clearly state the infection is with HIV-1.\n",
      "\n",
      "Answer: HIV-1\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2302 \n",
      "\n",
      "Evidence: These 23 patients were all male with a median age of 48 years (IQR 43–54 years). All except one were infected with a subtype B HIV-1.\n",
      "\n",
      "Rationale: The results section directly reports the subtypes, indicating predominantly subtype B with one non-B infection.\n",
      "\n",
      "Answer: Subtype B (all except one patient; one non-B subtype)\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2303 \n",
      "\n",
      "Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol. An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples collected retrospectively.\n",
      "\n",
      "Rationale: PR-RT refers to the protease (PR) and reverse transcriptase (RT) regions of pol; these were the sequenced genes.\n",
      "\n",
      "Answer: Protease (PR) and Reverse Transcriptase (RT) regions of pol\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2304 \n",
      "\n",
      "Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol. An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples collected retrospectively.\n",
      "\n",
      "Rationale: PR-RT are part of the HIV pol gene; thus, the study reports results from pol sequences.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2401 \n",
      "\n",
      "Evidence: Patients with PLLV were retrospectively selected from the cohort of HIV-1-infected patients followed at the Ghent University Hospital.\n",
      "\n",
      "Rationale: Ghent University Hospital is in Belgium; therefore, sequences are from Belgium.\n",
      "\n",
      "Answer: Belgium (Ghent)\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2402 \n",
      "\n",
      "Evidence: An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples collected retrospectively between 6 months post-ART initiation and January 2013 and all samples collected until study closure (February 2014). Follow-up started 6 months after antiretroviral therapy (ART) initiation and ended at virological failure or study closure (February 2014).\n",
      "\n",
      "Rationale: The paper specifies that retrospective sequencing covered up to January 2013 with additional sampling through February 2014; exact earlier start years are not provided.\n",
      "\n",
      "Answer: Through January 2013 (retrospective) and up to February 2014 (follow-up)\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2502 \n",
      "\n",
      "Evidence: Sequencing was performed on the ABI3130 Sequencer (Applied Biosystems, Foster City, CA, USA). Mixtures in sequences were identified if the secondary peak height was at least 20% of the dominant peak height at that position.\n",
      "\n",
      "Rationale: The ABI3130 is a capillary Sanger sequencer, indicating Sanger sequencing was used.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2503 \n",
      "\n",
      "Evidence: Sequencing was performed on the ABI3130 Sequencer (Applied Biosystems, Foster City, CA, USA). An ultrasensitive version of this protocol was used to sequence PR-RT ... and a three-step PCR was used instead of the two-step nested PCR.\n",
      "\n",
      "Rationale: The methods describe Sanger sequencing workflows and do not mention any next-generation sequencing technology.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2504 \n",
      "\n",
      "Evidence: Briefly, 20 µl of RNA extract was subjected to 60 min of reverse transcription at 45°C and 10 cycles of amplification ... Finally, a third PCR reaction of 40 cycles was performed using 2 µl of the second PCR product. Sequencing was performed on the ABI3130 Sequencer.\n",
      "\n",
      "Rationale: The protocol involves RT-PCR amplification from plasma RNA followed by direct sequencing; there is no mention of molecular cloning of amplicons prior to sequencing.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2505 \n",
      "\n",
      "Evidence: Finally, a third PCR reaction of 40 cycles was performed using 2 µl of the second PCR product. Sequencing was performed on the ABI3130 Sequencer.\n",
      "\n",
      "Rationale: The study used bulk PCR amplification rather than single-genome amplification; no single-genome sequencing was performed.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2506 \n",
      "\n",
      "Evidence: Briefly, 20 µl of RNA extract was subjected to ... amplification ... Finally, a third PCR reaction of 40 cycles was performed ... Sequencing was performed on the ABI3130 Sequencer.\n",
      "\n",
      "Rationale: The methods do not include molecular cloning; they directly sequenced PCR products.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2601 \n",
      "\n",
      "Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol. An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples collected retrospectively.\n",
      "\n",
      "Rationale: The study explicitly sequenced HIV from plasma samples.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2602 \n",
      "\n",
      "Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol. An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples collected retrospectively.\n",
      "\n",
      "Rationale: Only plasma samples are mentioned; there is no mention of PBMC-derived sequencing.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2603 \n",
      "\n",
      "Evidence: PR-RT amplification and sequencing was successful for 154 of the 378 samples. A sufficient amount of residual plasma for resistance analysis was available for 378 samples.\n",
      "\n",
      "Rationale: The successful sequencing count reported for plasma samples is 154.\n",
      "\n",
      "Answer: 154\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2604 \n",
      "\n",
      "Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol. An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples collected retrospectively.\n",
      "\n",
      "Rationale: The study did not report PBMC sequencing; therefore, the number of PBMC samples sequenced is zero.\n",
      "\n",
      "Answer: 0\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2605 \n",
      "\n",
      "Evidence: LLV was defined as a VL between 20 and 250 copies/ml. PLLV was defined as LLV in at least half of all VL measurements from 6 months after ART initiation until patient selection for the study (January 2013).\n",
      "\n",
      "Rationale: Individuals had persistent low-level viremia (detectable viral loads), indicating ongoing viraemia rather than complete suppression.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2606 \n",
      "\n",
      "Evidence: Briefly, 20 µl of RNA extract was subjected to ... reverse transcription ... An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples. \n",
      "\n",
      "Rationale: Sequencing was performed from plasma viral RNA; there is no indication of sequencing from proviral DNA reservoirs.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2701 \n",
      "\n",
      "Evidence: These 23 patients were all male with a median age of 48 years (IQR 43–54 years). \n",
      "\n",
      "Rationale: The reported ages indicate adult participants, and there is no mention of infants or children.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2702 \n",
      "\n",
      "Evidence: Patients with PLLV were retrospectively selected from the cohort of HIV-1-infected patients followed at the Ghent University Hospital. All patients provided written informed consent.\n",
      "\n",
      "Rationale: The paper describes an observational hospital cohort with ethics approval; it does not state whether any participants were in clinical trials.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2703 \n",
      "\n",
      "Evidence: Patients with PLLV were retrospectively selected from the cohort of HIV-1-infected patients followed at the Ghent University Hospital. All patients provided written informed consent.\n",
      "\n",
      "Rationale: There is no indication that all individuals were enrolled in a clinical trial; trial participation is not described.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 3101 \n",
      "\n",
      "Evidence: For the 28 selected PLLV patients a total of 590 VL measurements were performed during routine patient monitoring between initiation of ART and study closure. An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples collected retrospectively between 6 months post-ART initiation and January 2013 and all samples collected until study closure (February 2014).\n",
      "\n",
      "Rationale: The study applied the sequencing protocol to samples from the 28 selected patients, indicating these individuals had samples obtained for sequencing.\n",
      "\n",
      "Answer: 28\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 3102 \n",
      "\n",
      "Evidence: For the 28 selected PLLV patients ... A sufficient amount of residual plasma for resistance analysis was available for 378 samples ... PR-RT amplification and sequencing was successful for 154 of the 378 samples. To assess drug resistance during long-term follow-up, only patients with at least three genotyped longitudinal samples were included in further analysis (Table 1). These 23 patients were all male.\n",
      "\n",
      "Rationale: Although 28 patients were selected and sequencing was attempted, only 23 had at least three genotyped samples; the text does not state whether the remaining five had any successful sequencing at all.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4101 \n",
      "\n",
      "Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol.\n",
      "\n",
      "Rationale: This indicates sequencing of pre-ART (ART-naive) samples.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4102 \n",
      "\n",
      "Evidence: Ten (43.5%) patients were drugexperienced before study inclusion. An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples collected retrospectively between 6 months post-ART initiation and January 2013 and all samples collected until study closure (February 2014).\n",
      "\n",
      "Rationale: The cohort included ART-experienced individuals, and their samples were sequenced longitudinally.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4103 \n",
      "\n",
      "Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol. Ten (43.5%) patients were drugexperienced before study inclusion.\n",
      "\n",
      "Rationale: The study includes sequencing from both pre-ART (naive) samples and from ART-experienced individuals.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4104 \n",
      "\n",
      "Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol. \n",
      "\n",
      "Rationale: The paper does not provide a count of how many pre-ART samples were successfully sequenced; it only states that pre-ART samples were assessed.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4105 \n",
      "\n",
      "Evidence: Changes in treatment regimen were frequent, only five patients (21.7%) remained on the initial regimen during the study period and nine patients (39.1%) switched or intensified ART more than twice. Table 1 lists an Initial ART regimen and a Final ART regimen for each patient.\n",
      "\n",
      "Rationale: The paper provides initial and final regimens and summary switching frequency but not a complete, detailed ART history for each individual.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4201 \n",
      "\n",
      "Evidence: Patients with PLLV were retrospectively selected from the cohort of HIV-1-infected patients followed at the Ghent University Hospital. Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol.\n",
      "\n",
      "Rationale: Although pre-ART samples were assessed, the paper does not estimate or report the prevalence of transmitted drug resistance in a defined ART-naive population.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4202 \n",
      "\n",
      "Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol. Historical DRMs, detected before study initiation, were observed in three patients.\n",
      "\n",
      "Rationale: The detection of DRMs in pre-ART samples constitutes information on pretreatment drug resistance within this cohort.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4301 \n",
      "\n",
      "Evidence: Table 1 footnote: ABC, abacavir; ATV, atazanavir; AZT, zidovudine; DRM, drug resistance mutation; DRV, darunavir; EFV, efavirenz; ETV, etravirine; FTC, emtricitabine; LPV, lopinavir; MVC, maraviroc; r, ritonavir-boosted; RAL, raltegravir; TDF, tenofovir disoproxil fumarate; 3TC, lamivudine. Patient 6 Final ART regimen: DRVr+ABC+3TC+RAL.\n",
      "\n",
      "Rationale: The regimens listed include NRTIs (TDF, FTC, 3TC, ABC, AZT), NNRTIs (EFV, NVP, ETV), PIs (ATV/r, LPV/r, DRV/r), an INSTI (RAL), and a CCR5 antagonist (MVC).\n",
      "\n",
      "Answer: NRTIs, NNRTIs, Protease inhibitors, Integrase inhibitors, CCR5 antagonist\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4302 \n",
      "\n",
      "Evidence: Table 1 footnote includes RAL, raltegravir. Patient 20 Final ART regimen: RAL+TDF+FTC.\n",
      "\n",
      "Rationale: The presence of raltegravir-containing regimens indicates that some individuals received integrase inhibitors.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4303 \n",
      "\n",
      "Evidence: Table 1 footnote includes LPV, lopinavir; ATV, atazanavir; DRV, darunavir. Patient 13 Final ART regimen: DRVr+TDF+FTC.\n",
      "\n",
      "Rationale: Multiple regimens include ritonavir-boosted protease inhibitors (LPV/r, ATV/r, DRV/r), indicating PI use.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4304 \n",
      "\n",
      "Evidence: Changes in treatment regimen were frequent, only five patients (21.7%) remained on the initial regimen during the study period and nine patients (39.1%) switched or intensified ART more than twice.\n",
      "\n",
      "Rationale: The heterogeneity and frequent changes show that individuals did not all receive the same ART.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4305 \n",
      "\n",
      "Evidence: Patient 6 Final ART regimen: DRVr+ABC+3TC+RAL. Patient 20 Final ART regimen: RAL+TDF+FTC.\n",
      "\n",
      "Rationale: Because some individuals received an INSTI (raltegravir), not all were INSTI-naive.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4403 \n",
      "\n",
      "Evidence: Changes in treatment regimen were frequent, only five patients (21.7%) remained on the initial regimen during the study period. \n",
      "\n",
      "Rationale: If only 5 of 23 stayed on their initial regimen, then 23−5 = 18 individuals received more than one regimen.\n",
      "\n",
      "Answer: 18\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4404 \n",
      "\n",
      "Evidence: Nine patients (39.1%) switched or intensified ART more than twice.\n",
      "\n",
      "Rationale: The paper reports how many switched more than twice but does not provide enough detail to determine exactly how many received more than two distinct regimens (e.g., those who switched exactly twice would also have >2 regimens but are not quantified).\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4405 \n",
      "\n",
      "Evidence: Changes in treatment regimen were frequent, only five patients (21.7%) remained on the initial regimen during the study period and nine patients (39.1%) switched or intensified ART more than twice.\n",
      "\n",
      "Rationale: The number of regimen changes varied across individuals, indicating they did not all receive the same number of regimens.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4406 \n",
      "\n",
      "Evidence: Only five patients (21.7%) remained on the initial regimen during the study period.\n",
      "\n",
      "Rationale: Since only a minority stayed on a single regimen, not all individuals received only one ART regimen.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4501 \n",
      "\n",
      "Evidence: Table 1 footnote lists RAL (raltegravir) and MVC (maraviroc) among others, but dolutegravir is not mentioned anywhere in the regimens. Patient 20 Final ART regimen: RAL+TDF+FTC.\n",
      "\n",
      "Rationale: The regimens include raltegravir as the INSTI; there is no mention of dolutegravir use.\n",
      "\n",
      "Answer: 0\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4502 \n",
      "\n",
      "Evidence: Table 1 footnote includes DRV, darunavir. Multiple Final ART regimens include DRVr (e.g., patients 1, 2, 3, 6, 10, 13, 14, 15, 16, 18, 19, 22, 23).\n",
      "\n",
      "Rationale: Counting individuals with darunavir-containing regimens in Table 1 yields 13 persons.\n",
      "\n",
      "Answer: 13\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 5101 \n",
      "\n",
      "Evidence: Historical DRMs, detected before study initiation, were observed in three patients. New DRM, not present at study initiation or in earlier samples, were found in four isolated samples from four different patients: K101E in patient 1, Y188C in patient 13, I50L in patient 19 and K219E in patient 21.\n",
      "\n",
      "Rationale: Unique individuals with DRMs are patients 12, 13, 14 (historical) and 1, 19, 21 (new); patient 13 appears in both groups, yielding 6 individuals with one or more DRMs.\n",
      "\n",
      "Answer: 6\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 5102 \n",
      "\n",
      "Evidence: Resistance mutations in PR-RT were assessed. New DRM detected were K101E, Y188C, I50L and K219E.\n",
      "\n",
      "Rationale: Only protease and reverse transcriptase regions were sequenced and reported; no integrase resistance mutations were examined or found.\n",
      "\n",
      "Answer: 0\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 5103 \n",
      "\n",
      "Evidence: Historical DRMs included D67N, T69D and T215C. New DRM detected were K101E, Y188C, I50L and K219E.\n",
      "\n",
      "Rationale: None of the reported mutations are the canonical TDF-associated resistance mutations (e.g., K65R); therefore, no individuals had TDF-resistance mutations.\n",
      "\n",
      "Answer: 0\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 5104 \n",
      "\n",
      "Evidence: Resistance mutations in PR-RT were assessed. New DRM detected were K101E, Y188C, I50L and K219E.\n",
      "\n",
      "Rationale: The study did not sequence integrase and reports no INSTI resistance mutations.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 6101 \n",
      "\n",
      "Evidence: Sequencing was performed on the ABI3130 Sequencer ... and sequences were analysed using SmartGene ... DRM were defined as mutations with a score >10 according to the Stanford HIV Drug Resistance Database.\n",
      "\n",
      "Rationale: The paper reports only genotypic analyses; no phenotypic susceptibility testing methods are described.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 6102 \n",
      "\n",
      "Evidence: DRM were defined as mutations with a score >10 according to the Stanford HIV Drug Resistance Database. Sequencing was performed on the ABI3130 Sequencer.\n",
      "\n",
      "Rationale: There is no mention of IC50 or IC90 determinations in the text.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 6103 \n",
      "\n",
      "Evidence: DRM were defined as mutations with a score >10 according to the Stanford HIV Drug Resistance Database. Sequencing was performed on the ABI3130 Sequencer.\n",
      "\n",
      "Rationale: The paper contains no phenotypic fold-change data.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 6104 \n",
      "\n",
      "Evidence: Sequencing was performed on the ABI3130 Sequencer ... DRM were defined as mutations with a score >10 according to the Stanford HIV Drug Resistance Database.\n",
      "\n",
      "Rationale: No phenotypic susceptibility assay is described.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 6105 \n",
      "\n",
      "Evidence: The modifications for the ultrasensitive protocol consisted of ... PCR ... Sequencing was performed on the ABI3130 Sequencer. \n",
      "\n",
      "Rationale: There is no mention of replication capacity measurements in the methods or results.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 6106 \n",
      "\n",
      "Evidence: Sequencing was performed on the ABI3130 Sequencer ... DRM were defined as mutations with a score >10 according to the Stanford HIV Drug Resistance Database.\n",
      "\n",
      "Rationale: No phenotypic testing of drugs was performed; therefore, no drugs were tested for phenotypic susceptibility.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 7101 \n",
      "\n",
      "Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample ... and ... in all plasma samples collected retrospectively ... Sequencing was performed on the ABI3130 Sequencer.\n",
      "\n",
      "Rationale: The study sequenced viruses directly from patient plasma; there is no description of site-directed mutagenesis constructs.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 7102 \n",
      "\n",
      "Evidence: An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples collected retrospectively between 6 months post-ART initiation and January 2013 and all samples collected until study closure (February 2014). \n",
      "\n",
      "Rationale: The paper analyzes clinical samples and does not report any in vitro passage experiments.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n"
     ]
    }
   ],
   "source": [
    "# gpt-4o\n",
    "\n",
    "model = \"gpt-5\"\n",
    "file_path = Path(\"papers 250\") / \"60\"\n",
    "rows = []\n",
    "\n",
    "with open(\"explain_multi_questions.txt\", \"r\", encoding=\"utf-8\") as f:\n",
    "    template = f.read()\n",
    "\n",
    "tmp_content = None\n",
    "tmp_name = None\n",
    "for folder in file_path.iterdir():\n",
    "    if folder.is_dir():\n",
    "        doc_folder = folder / \"document\"\n",
    "        if doc_folder.exists():\n",
    "            for md_file in doc_folder.glob(\"*.checked.md\"):\n",
    "                with md_file.open(encoding=\"utf-8\") as f:\n",
    "                    content = f.read()\n",
    "                    #test 1 first\n",
    "                    tmp_name = md_file.stem.replace(\".checked\", \"\")  # Remove the .checked part\n",
    "                    tmp_content = content\n",
    "\n",
    "                    output_file = Path(f\"Results/{model}/{tmp_name}/60_questions_answer.txt\")\n",
    "                \n",
    "                    # Skip if output file already exists\n",
    "                    if output_file.exists():\n",
    "                        print(f\"Skipping {tmp_name}, output file already exists.\")\n",
    "                        continue\n",
    "\n",
    "                    \n",
    "\n",
    "                    prompt_60 = template.format(\n",
    "                        paper_content=tmp_content,\n",
    "                        question=questions_block.strip()\n",
    "                    )\n",
    "\n",
    "                    # --- Step 6: Save final prompt ---\n",
    "                    # output_file = Path(f\"Results/{model}/{tmp_name}/_60_questions_prompt.txt\")\n",
    "                    # with output_file.open(\"w\", encoding=\"utf-8\") as f:\n",
    "                    #     f.write(prompt_60)\n",
    "                    # print(prompt_60)\n",
    "\n",
    "                    \n",
    "                    answer = complete_with_continuation(prompt_60, model=model, save_path = Path(f\"Results/{model}/{tmp_name}/cost.xlsx\"), max_tokens=4096)\n",
    "\n",
    "                    print(answer)\n",
    "                    output_file = Path(f\"Results/{model}/{tmp_name}/60_questions_answer.txt\")\n",
    "\n",
    "\n",
    "                    # Create the parent directories if they don't exist\n",
    "                    output_file.parent.mkdir(parents=True, exist_ok=True)\n",
    "                    with output_file.open(\"w\", encoding=\"utf-8\") as f:\n",
    "                        f.write(answer)\n",
    "                    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "db79a03c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "--- API Call Usage ---\n",
      "Input tokens: 6436\n",
      "Cached input tokens: 0\n",
      "Output tokens: 14692\n",
      "Total tokens: 21128\n",
      "Estimated cost (this call): $0.006199\n",
      "\n",
      "=== Total Usage Across All Calls ===\n",
      "Input tokens: 6436\n",
      "Cached input tokens: 0\n",
      "Output tokens: 14692\n",
      "Grand total tokens: 21128\n",
      "Estimated total cost: $0.006199\n",
      "\"\"\"\n",
      "Question: 1101 \n",
      "\n",
      "Evidence: From December 2017 through May 2018, a total of 276 youth age 15 and 24 years from four clinics were recruited into the parent Project YES! study. A cross-sectional analysis of all HIVDR results at study enrollment was done to determine HIVDR prevalence and characteristics among adolescents and young adults with virologic treatment failure.\n",
      "\n",
      "Rationale: The study presents newly collected enrollment data and conducts a cross-sectional analysis of HIV drug resistance results, indicating the data are from a new, unpublished study.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 1102 \n",
      "\n",
      "Evidence: HIV viral load was determined using the Cobas Ampliprep/CobasTaqman 96 machine. Blood samples with a viral load of >1000 copies/mL were further subjected to an HIV drug resistance test using an Applied Biosystems Genetic Analyzer model 3500XL. Genotyping encompassed protease and codons 1--230 of reverse-transcriptase genes.\n",
      "\n",
      "Rationale: These sentences show that sequencing/genotyping was performed on samples with virologic failure, i.e., HIV sequences were generated for resistance testing.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 1103 \n",
      "\n",
      "Evidence: The paper describes a cross-sectional analysis of HIVDR results and does not mention any in vitro passage experiments. It focuses on resistance mutations identified from Genotyping of protease and RT genes in plasma samples with VL ≥1000 copies/mL.\n",
      "\n",
      "Rationale: The methods and results pertain to cross-sectional genotypic resistance testing, with no reference to in vitro passage experiments.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 1104 \n",
      "\n",
      "Evidence: HIVDR was defined as the presence of at least one drug resistance–associated mutation (DRM) according to the WHO 2009 Surveillance Drug Resistance Mutation list, using the Stanford Calibrated Population Resistance analysis tool. The outcomes of the HIV resistance tests were reported using the Stanford HIV drug resistance database. There is no mention of phenotypic susceptibility testing or phenotypic drug susceptibility data.\n",
      "\n",
      "Rationale: The study relies on genotypic resistance testing and database interpretation, not phenotypic assays.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2101 \n",
      "\n",
      "Evidence: The outcomes of the HIV resistance tests were reported using the Stanford HIV drug resistance database at http://hivdb.stanford.edu/. There is no mention of GenBank accession numbers for sequenced isolates in the text provided.\n",
      "\n",
      "Rationale: The methods and results cite a database-based interpretation rather than deposition of sequences in GenBank.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2102 \n",
      "\n",
      "Evidence: The paper describes sequencing and reporting of resistance mutations via the Stanford HIV drug resistance database, with no explicit GenBank accession numbers listed for any isolates.\n",
      "\n",
      "Rationale: There is no GenBank accession number information presented in the provided content.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2103 \n",
      "\n",
      "Evidence: The paper states that HIVDR results were reported using the Stanford HIV drug resistance database and provides tables of mutation frequencies, but does not provide any GenBank accession numbers.\n",
      "\n",
      "Rationale: The absence of GenBank accession numbers in the methods/results text supports that none are reported.\n",
      "\n",
      "Answer: None reported\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2202 \n",
      "\n",
      "Evidence: Table 3 presents the \"Distribution of HIV drug resistance mutations in the sample with any HIVDR (n = 58)\" and lists frequencies for individual mutations (e.g., M184V 81.0%, K103N 65.5%), rather than per-isolate mutation lists.\n",
      "\n",
      "Rationale: The paper provides aggregated mutation frequencies, not lists of mutations for individual isolates.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2301 \n",
      "\n",
      "Evidence: The study involved HIV-1 RNA from plasma; the abstract/title references \"HIV drug resistance among ART experienced adolescents and young adults living with HIV\" in Ndola, Zambia, with sequence-based resistance testing.\n",
      "\n",
      "Rationale: The paper concerns HIV-1, not other HIV species.\n",
      "\n",
      "Answer: HIV-1\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2302 \n",
      "\n",
      "Evidence: There is no discussion of HIV subtypes in the provided content. The sequencing focuses on protease and RT genes; no subtype analysis is described.\n",
      "\n",
      "Rationale: Subtype information is not present in the text.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2303 \n",
      "\n",
      "Evidence: \"Genotyping encompassed protease and codons 1--230 of reverse-transcriptase genes.\" This explicitly states the genes sequenced.\n",
      "\n",
      "Rationale: The sequenced genes are protease and reverse-transcriptase (RT), i.e., parts of the pol gene.\n",
      "\n",
      "Answer: Protease and reverse-transcriptase (RT) genes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2304 \n",
      "\n",
      "Evidence: The study reports DRM results across NRTI, NNRTI, and PI mutations (Tables 3 and related text). This pertains to pol-region mutations and resistance interpretation.\n",
      "\n",
      "Rationale: The results concern genotypic DRM in NRTI/NNRTI/PI, which are pol mutations.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2401 \n",
      "\n",
      "Evidence: The study was conducted in Ndola, Zambia, as stated in the title and methods. Four clinics in Ndola are mentioned.\n",
      "\n",
      "Rationale: The geographic sources are Ndola, Zambia.\n",
      "\n",
      "Answer: Zambia\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2402 \n",
      "\n",
      "Evidence: The enrollment period is stated as December 2017 through May 2018.\n",
      "\n",
      "Rationale: The years of sample collection align with 2017–2018.\n",
      "\n",
      "Answer: 2017–2018\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2502 \n",
      "\n",
      "Evidence: \"Applied Biosystems Genetic Analyzer model 3500XL\" used for HIVDR testing; \"Sequences were assembled and manually edited using Sequencer version 4.5 software.\" The 3500XL is a capillary electrophoresis instrument used for Sanger sequencing.\n",
      "\n",
      "Rationale: Documentation points to Sanger-style sequencing rather than NGS.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2503 \n",
      "\n",
      "Evidence: The sequencing method described uses a Capillary/Applied Biosystems 3500XL instrument and sequence assembly/editing with Sequencer software, consistent with Sanger sequencing rather than NGS.\n",
      "\n",
      "Rationale: No mention of NGS platforms; the description aligns with Sanger sequencing.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2504 \n",
      "\n",
      "Evidence: The methods describe RNA extraction, sequencing of protease and RT genes, and assembly/editing, but there is no mention of cloning steps prior to sequencing.\n",
      "\n",
      "Rationale: No cloning steps are described in the sequencing workflow.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2505 \n",
      "\n",
      "Evidence: The sequencing workflow describes direct sequencing of RT and protease regions from RNA (plasma) without reference to single-genome sequencing or other genome-wide methods.\n",
      "\n",
      "Rationale: There is no indication of single-genome sequencing.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2506 \n",
      "\n",
      "Evidence: There is no mention of molecular cloning steps in the Methods or Results sections.\n",
      "\n",
      "Rationale: The sequencing workflow did not include cloning steps.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2601 \n",
      "\n",
      "Evidence: \"Blood samples for HIV viral load testing...\" and \"HIV viral load results were used to select samples for HIVDR testing from plasma\" and \"Genotyping encompassed protease and codons 1--230 of reverse-transcriptase genes.\" The sequencing is performed on plasma-derived material.\n",
      "\n",
      "Rationale: The sequencing results come from plasma, i.e., plasma HIV sequencing.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2602 \n",
      "\n",
      "Evidence: The Methods describe sequencing from plasma and do not mention PBMC sequencing. The statement about sequencing context implies plasma-derived sequences.\n",
      "\n",
      "Rationale: PBMC sequencing is not described.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2603 \n",
      "\n",
      "Evidence: \"Amplification was successful in 77.8% (n = 77)\" among the 99 with VL ≥1000 copies/mL. This indicates 77 samples underwent sequencing/sequencing-based resistance testing.\n",
      "\n",
      "Rationale: This number corresponds to the plasma samples that yielded HIVDR sequences.\n",
      "\n",
      "Answer: 77\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2604 \n",
      "\n",
      "Evidence: No PBMC sequencing is described; only plasma-based sequencing is reported.\n",
      "\n",
      "Rationale: The manuscript discusses plasma-derived sequencing without PBMC data.\n",
      "\n",
      "Answer: 0\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2605 \n",
      "\n",
      "Evidence: The selection criterion for sequencing was VL ≥1000 copies/mL, i.e., active HIV replication; the results discuss mutations found in those with virologic failure.\n",
      "\n",
      "Rationale: This confirms sequencing was performed on samples from individuals with active replication.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2606 \n",
      "\n",
      "Evidence: The Methods state that HIVDR testing was interpreted via the Stanford database and there is explicit mention that integrase gene regions were not tested (no INSTI mutations reported). The text does not describe assays for proviral DNA reservoir.\n",
      "\n",
      "Rationale: There is no discussion of sequencing from proviral DNA reservoir or integrase region in the methodology/results.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2701 \n",
      "\n",
      "Evidence: The study population comprises youth aged 15–24 years. There is no mention of infants or young children.\n",
      "\n",
      "Rationale: The age range indicates this is not infant/child sequencing.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2702 \n",
      "\n",
      "Evidence: \"once consented and enrolled into the study, Interviews and blood draws for viral load and HIVDR were done after which study participants were randomized to the intervention or delayed intervention arms.\"\n",
      "\n",
      "Rationale: This confirms that some individuals were in a clinical trial.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 2703 \n",
      "\n",
      "Evidence: Only a subset of the Project YES! participants underwent sequencing for HIVDR testing (n = 77 of 273 with enrollment VL results). Not all participants were in a randomized phase relevant to sequencing.\n",
      "\n",
      "Rationale: Not all individuals in the study had sequencing data.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 3101 \n",
      "\n",
      "Evidence: \"Among the 77 youth with HIVDR results ...\" and \"n = 77\" in several places, indicating 77 individuals had samples with sequencing results.\n",
      "\n",
      "Rationale: This is the number of individuals with sequencing results.\n",
      "\n",
      "Answer: 77\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 3102 \n",
      "\n",
      "Evidence: The study enrolled 273 participants with VL results, but only 77 had HIVDR amplification successfully. The text states \"Among the 273 participants... 99 had VL ≥1000 copies/mL; Amplification was successful in 77.8% (n = 77).\"\n",
      "\n",
      "Rationale: Not all individuals underwent HIVDR sequencing.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4101 \n",
      "\n",
      "Evidence: All sequencing participants were ART-experienced (eligibility included ART for at least 6 months; there is no indication that ART-naive individuals were included). The ART contexts describe regimens used in first/second lines and do not reflect ART-naive samples.\n",
      "\n",
      "Rationale: The cohort is described as ART-experienced.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4102 \n",
      "\n",
      "Evidence: The study context describes regimens and HIVDR testing among ART-experienced youth; \"the HIV treatment context\" indicates prevalent ART exposure.\n",
      "\n",
      "Rationale: The subject population is ART-experienced.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4103 \n",
      "\n",
      "Evidence: The text notes dolutegravir had not been introduced during the study's early phase, with raltegravir available as a third-line option, implying a lack of both ART-naive and ART-experienced mixture in terms of INSTI exposure within this cohort; all participants were described in the context of ART-experienced regimens, not a mix including ART-naive.\n",
      "\n",
      "Rationale: The study emphasizes ART-experienced regimens and limited INSTI use.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4104 \n",
      "\n",
      "Evidence: The paper cites treatment regimens (First line and Second line, with specific drug combinations) and notes inadequacies in chart documentation for reasons for drug changes; It indicates no universal ART history completeness.\n",
      "\n",
      "Rationale: There were variable durations and changes in regimens, with incomplete documentation.\n",
      "\n",
      "Answer: 0\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4105 \n",
      "\n",
      "Evidence: \"Unfortunately, there has been inadequate documentation of reasons for drug changes in most study participants medical charts.\" This indicates incomplete ART history information.\n",
      "\n",
      "Rationale: The paper itself notes incomplete ART histories.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4201 \n",
      "\n",
      "Evidence: The study reports prevalence of resistance mutations among those with virologic failure and does not address transmitted drug resistance or pretreatment resistance in ART-naive individuals.\n",
      "\n",
      "Rationale: The focus is on resistance after treatment exposure, not pretreatment or transmitted resistance in general.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4202 \n",
      "\n",
      "Evidence: The study design and results pertain to ART-experienced individuals with virologic failure and do not provide pretreatment resistance prevalence.\n",
      "\n",
      "Rationale: Pretreatment resistance prevalence is not addressed in this cross-sectional, treated cohort.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4301 \n",
      "\n",
      "Evidence: First-line regimens included Tenofovir/Lamivudine/Efavirenz; second-line regimens included Zidovudine/Lamivudine/Lopinavir/ritonavir; third-line options included raltegravir and other PIs. Table 2 shows first-line and second-line regimens; Table notes on lines and specific drugs.\n",
      "\n",
      "Rationale: The paper lists the drug classes received by individuals (NRTIs/NtRTIs, NNRTIs, PIs).\n",
      "\n",
      "Answer: NRTIs/NtRTIs, NNRTIs, and PIs\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4302 \n",
      "\n",
      "Evidence: It is stated that dolutegravir had not been introduced to the public health sector until late in the intervention phase and raltegravir was the only integrase inhibitor available for use as a third-line ART. There is no explicit data showing individuals who actually received INSTIs.\n",
      "\n",
      "Rationale: The text discusses INSTI availability and limited usage, but not actual recipients.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4303 \n",
      "\n",
      "Evidence: The second-line regimens include Lopinavir/ritonavir and Atazanavir/ritonavir; Third-line options include raltegravir; The description clearly mentions protease inhibitors among regimens.\n",
      "\n",
      "Rationale: This confirms PI use among individuals.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4304 \n",
      "\n",
      "Evidence: The regimens vary by line (first, second, third line) and include different drugs; Not all individuals received the same ART.\n",
      "\n",
      "Rationale: There is heterogeneity in regimens.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4305 \n",
      "\n",
      "Evidence: The paper notes that dolutegravir had not been introduced and that raltegravir was the only INSTI available; It also mentions that HIVDR testing did not cover integrase regions. All participants appear to be ART-experienced and INSTI-naive in practice.\n",
      "\n",
      "Rationale: INSTIs were not broadly used in this cohort.\n",
      "\n",
      "Answer: Yes\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4403 \n",
      "\n",
      "Evidence: \"Out of the 48, 3 participants were on second-line treatment and needed to switch to third line, and 45 of the participants were on first line and needed to be changed to a second line ART regimen.\" Therefore, 48 individuals needed more than one ART regimen.\n",
      "\n",
      "Rationale: This directly states the count of individuals who required more than one regimen.\n",
      "\n",
      "Answer: 48\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4404 \n",
      "\n",
      "Evidence: The same sentence notes that 3 participants needed to switch to third line; the rest required at most two lines; This implies that more than two regimens were needed for 3 individuals.\n",
      "\n",
      "Rationale: The data indicate three individuals had three regimens.\n",
      "\n",
      "Answer: 3\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4405 \n",
      "\n",
      "Evidence: \"45 of the participants were on first line and needed to be changed to a second line ART regimen\" and \"3 participants on second line needed to switch to third line\" indicate not all had the same number of regimens.\n",
      "\n",
      "Rationale: There is variability in the number of regimens across participants.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4406 \n",
      "\n",
      "Evidence: Given the distribution (some changing from first to second line, and a few from second to third), not all participants received the same number of regimens.\n",
      "\n",
      "Rationale: There was variation, as described in the results.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4501 \n",
      "\n",
      "Evidence: The text states that dolutegravir had not been introduced to the public health sector until late in the intervention phase of this study; it implies no participants received dolutegravir during most of the study period.\n",
      "\n",
      "Rationale: INSTI exposure (dolutegravir) appears not to have occurred among participants in the early phase.\n",
      "\n",
      "Answer: 0\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 4502 \n",
      "\n",
      "Evidence: The only INSTI explicitly available for third-line use is raltegravir; there is no mention of darunavir as an INSTI (darunavir is a PI). The text does not indicate any participants received darunavir.\n",
      "\n",
      "Rationale: Darunavir is a PI, not an INSTI; there is no evidence of darunavir usage.\n",
      "\n",
      "Answer: 0\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 5101 \n",
      "\n",
      "Evidence: Among 77 participants with HIVDR results, 58 had any resistance (75.3%).\n",
      "\n",
      "Rationale: This provides the count of individuals with one or more DRM.\n",
      "\n",
      "Answer: 58\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 5102 \n",
      "\n",
      "Evidence: The paper notes that HIVDR testing did not test for integrase inhibitor gene regions, and there is no report of INSTI-resistance mutations.\n",
      "\n",
      "Rationale: There were 0 reported INSTI-resistance mutations.\n",
      "\n",
      "Answer: 0\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 5103 \n",
      "\n",
      "Evidence: K65R mutation appears in 20 (34.5%) of the samples with HIVDR; K65R confers resistance to tenofovir, and the table shows 20 individuals with K65R.\n",
      "\n",
      "Rationale: The data specify the frequency of the K65R mutation.\n",
      "\n",
      "Answer: 20\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 5104 \n",
      "\n",
      "Evidence: The INSTI-resistance mutations are not reported; INSTI testing regions were not tested. The only INSTI mentioned is raltegravir as a third-line option, with no specific INSTI-resistance mutations reported.\n",
      "\n",
      "Rationale: No INSTI-resistance mutations are described in the study results.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 6101 \n",
      "\n",
      "Evidence: The study used genotypic HIVDR testing interpreted via the Stanford database; there is no phenotypic susceptibility assay described.\n",
      "\n",
      "Rationale: Phenotypic susceptibility testing is not reported.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 6102 \n",
      "\n",
      "Evidence: No IC values or IC50/IC90 data are reported; the methods focus on genotypic resistance interpretation.\n",
      "\n",
      "Rationale: The study does not present phenotypic susceptibility metrics.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 6103 \n",
      "\n",
      "Evidence: No IC50 fold change values are reported; the results are expressed as mutation frequencies and resistance classifications from genotypic analysis.\n",
      "\n",
      "Rationale: The data are genotypic, not phenotypic.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 6104 \n",
      "\n",
      "Evidence: There is no phenotypic susceptibility assay described; the study relies on genotypic resistance testing and database interpretation.\n",
      "\n",
      "Rationale: The methods specify genotypic testing rather than phenotypic assays.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 6105 \n",
      "\n",
      "Evidence: The paper does not discuss replication capacity or other phenotypic replication metrics.\n",
      "\n",
      "Rationale: No replication capacity data are presented.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 6106 \n",
      "\n",
      "Evidence: The study does not report phenotypic susceptibility testing or drug-specific replication data; it relies on genotypic resistance data.\n",
      "\n",
      "Rationale: No phenotypic testing details are provided.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 7101 \n",
      "\n",
      "Evidence: The paper does not describe site-directed mutations or isolates resulting from site-directed mutagenesis; it focuses on clinical samples and observed DRM frequencies.\n",
      "\n",
      "Rationale: No site-directed mutations are reported.\n",
      "\n",
      "Answer: NA\n",
      "\"\"\"\n",
      "\n",
      "\"\"\"\n",
      "Question: 7102 \n",
      "\n",
      "Evidence: There are no in vitro passage experiments described; the study is cross-sectional with sequencing of plasma RNA from participants with virologic failure.\n",
      "\n",
      "Rationale: The paper does not report in vitro passage experiments.\n",
      "\n",
      "Answer: No\n",
      "\"\"\"\n"
     ]
    }
   ],
   "source": [
    "\n",
    "\n",
    "\n",
    "\n",
    "pattern = r\"Question:\\s*(.*?)\\s*Evidence:\\s*(.*?)\\s*Rationale:\\s*(.*?)\\s*Answer:\\s*(.*?)(?=\\n---|\\nQuestion:|$)\"\n",
    "\n",
    "\n",
    "base_dir = Path(f\"Results/{model}\")\n",
    "\n",
    "# Loop over every folder in base_dir\n",
    "for tmp_folder in base_dir.iterdir():\n",
    "    if tmp_folder.is_dir():\n",
    "        file_path = tmp_folder / \"60_questions_answer.txt\"\n",
    "        if file_path.exists():\n",
    "            # Read the file\n",
    "            with open(file_path, \"r\") as f:\n",
    "                content = f.read()\n",
    "            \n",
    "\n",
    "    # for text file in output_file = Path(f\"Results/{model}/{tmp_name}/60_questions_answer.txt\")\n",
    "\n",
    "    matches = re.findall(pattern, content, re.DOTALL)\n",
    "\n",
    "    # --- Step 3: Build dataframe ---\n",
    "    records = []\n",
    "\n",
    "    for i, (q, ev, rat, ans) in enumerate(matches):\n",
    "        # strip extra whitespace\n",
    "        q, ev, rat, ans = q.strip(), ev.strip(), rat.strip(), ans.strip()\n",
    "\n",
    "        # Clean the answer\n",
    "        cleaned_ans = ans.replace(\"\\n\", \" \")         # remove line breaks\n",
    "        cleaned_ans = re.sub(r'\"+', '', cleaned_ans) # remove repeated quotes\n",
    "        cleaned_ans = re.sub(r'\\s+', ' ', cleaned_ans).strip()  # collapse multiple spaces\n",
    "        \n",
    "        # match to QID + original Question\n",
    "        if i < len(combined_list):\n",
    "            id_str, question_str = combined_list[i].split(\": \", 1)\n",
    "            records.append({\n",
    "                \"PMID\": tmp_name,\n",
    "                \"QID\": id_str,\n",
    "                \"Question\": question_str,\n",
    "                \"Evidence\": ev,\n",
    "                \"Rationale\": rat,\n",
    "                \"Answer\": cleaned_ans\n",
    "            })\n",
    "\n",
    "    output_df = pd.DataFrame(records)\n",
    "\n",
    "    # --- Step 4: Save to Excel ---\n",
    "    output_df.to_excel(f\"Results/{model}/{tmp_folder}/gpt_answers_60.xlsx\", index=False)\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "37f1cfe4",
   "metadata": {},
   "source": [
    "## Claude results"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "8bde4327",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Input tokens: 5262\n",
      "Output tokens: 3866\n",
      "Total tokens: 9128\n",
      "Estimated cost: $0.3689\n"
     ]
    }
   ],
   "source": [
    "from anthropic import Anthropic\n",
    "client = Anthropic(api_key=claude_api_key)\n",
    "\n",
    "response = client.messages.create(\n",
    "    model=\"claude-3-haiku-20240307\", # claude-3-haiku-20240307\n",
    "    max_tokens=4096,\n",
    "    messages=[\n",
    "        {\"role\": \"user\", \"content\": prompt_60}\n",
    "    ]\n",
    ")\n",
    "\n",
    "answer = response.content[0].text\n",
    "\n",
    "# --- Step 1: Token usage ---\n",
    "input_tokens = response.usage.input_tokens\n",
    "output_tokens = response.usage.output_tokens\n",
    "total_tokens = input_tokens + output_tokens\n",
    "\n",
    "print(f\"Input tokens: {input_tokens}\")\n",
    "print(f\"Output tokens: {output_tokens}\")\n",
    "print(f\"Total tokens: {total_tokens}\")\n",
    "\n",
    "# --- Step 2: Pricing (Claude Opus 4.1 as of 2025-09) ---\n",
    "# Input: $15.00 per 1M tokens = $0.000015 per token\n",
    "# Output: $75.00 per 1M tokens = $0.000075 per token\n",
    "input_cost = input_tokens * 0.000015\n",
    "output_cost = output_tokens * 0.000075\n",
    "total_cost = input_cost + output_cost\n",
    "\n",
    "print(f\"Estimated cost: ${total_cost:.4f}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "15bc1cad",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Here are the answers to the questions:\n",
      "\n",
      "Question: 1101\n",
      "\n",
      "Evidence: The paper states that \"The epidemic characteristics of human immunodeficiency virus type 1 (HIV-1) in Zhejiang Province have not been systematically identified.\" This suggests that the data reported in the paper are previously unpublished.\n",
      "\n",
      "Rationale: The paper presents new data on the epidemic characteristics and molecular epidemiology of HIV-1 in Zhejiang Province, China, which has not been systematically studied before.\n",
      "\n",
      "Answer: Yes\n",
      "\n",
      "Question: 1102\n",
      "\n",
      "Evidence: The paper states that \"Totally, 332 *gag* and 229 *pol* gene fragments were amplified and sequenced from the 451 individual samples, respectively.\"\n",
      "\n",
      "Rationale: The paper reports the sequencing of HIV-1 gag and pol gene fragments from patient samples.\n",
      "\n",
      "Answer: Yes\n",
      "\n",
      "Question: 1103 \n",
      "\n",
      "Evidence: There is no mention of in vitro passage experiments in the paper.\n",
      "\n",
      "Rationale: The paper does not report any results from in vitro passage experiments.\n",
      "\n",
      "Answer: No\n",
      "\n",
      "Question: 1104\n",
      "\n",
      "Evidence: The paper does not report any in vitro antiretroviral susceptibility data.\n",
      "\n",
      "Rationale: The paper focuses on the molecular epidemiology and subtype distribution of HIV-1 in Zhejiang Province and does not include any in vitro antiretroviral susceptibility data.\n",
      "\n",
      "Answer: No\n",
      "\n",
      "Question: 2101\n",
      "\n",
      "Evidence: The paper states that \"The HIV sequences are accessible in GenBank from KJ613998 to KJ614226 (Pol) and from KJ613666to KJ613997 (Gag).\"\n",
      "\n",
      "Rationale: The paper reports GenBank accession numbers for the sequenced HIV isolates.\n",
      "\n",
      "Answer: Yes\n",
      "\n",
      "Question: 2102\n",
      "\n",
      "Evidence: The paper states that the GenBank accession numbers reported are for the sequenced HIV isolates, not laboratory HIV isolates.\n",
      "\n",
      "Rationale: The GenBank accession numbers are for the clinical HIV-1 samples sequenced in this study, not laboratory strains.\n",
      "\n",
      "Answer: Yes\n",
      "\n",
      "Question: 2103\n",
      "\n",
      "Evidence: The paper reports the following GenBank accession numbers:\n",
      "- KJ613998 to KJ614226 for pol gene sequences\n",
      "- KJ613666 to KJ613997 for gag gene sequences\n",
      "\n",
      "Rationale: The paper explicitly lists the GenBank accession number ranges for the sequenced HIV-1 pol and gag gene fragments.\n",
      "\n",
      "Answer: KJ613998 to KJ614226 (pol) and KJ613666 to KJ613997 (gag)\n",
      "\n",
      "Question: 2202\n",
      "\n",
      "Evidence: The paper does not report lists of mutations for individual sequenced HIV isolates.\n",
      "\n",
      "Rationale: The paper focuses on the subtype distribution and molecular epidemiology of HIV-1 in Zhejiang province, and does not provide detailed mutation information for the sequenced isolates.\n",
      "\n",
      "Answer: No\n",
      "\n",
      "Question: 2301\n",
      "\n",
      "Evidence: The paper states that the study focused on \"human immunodeficiency virus type 1 (HIV-1)\".\n",
      "\n",
      "Rationale: The paper clearly indicates that the HIV species studied was HIV-1.\n",
      "\n",
      "Answer: HIV-1\n",
      "\n",
      "Question: 2302\n",
      "\n",
      "Evidence: The paper reports the detection of the following HIV-1 subtypes and circulating recombinant forms (CRFs) in Zhejiang province: \n",
      "\"CRF01_AE, B/B', CRF07_BC, CRF08_BC, CRF02_AG, CRF06_CPX, and some novel recombinant strains.\"\n",
      "\n",
      "Rationale: The paper comprehensively lists the different HIV-1 subtypes and CRFs identified in the study.\n",
      "\n",
      "Answer: CRF01_AE, B/B', CRF07_BC, CRF08_BC, CRF02_AG, CRF06_CPX, and novel recombinant strains\n",
      "\n",
      "Question: 2303\n",
      "\n",
      "Evidence: The paper states that \"the gag or env gene sequences were obtained. In drug resistance surveillance, only pol gene was harvested.\"\n",
      "\n",
      "Rationale: The paper reports the sequencing of HIV-1 gag and pol gene fragments.\n",
      "\n",
      "Answer: gag and pol\n",
      "\n",
      "Question: 2304\n",
      "\n",
      "Evidence: The paper states that \"229 *pol* gene fragments were amplified and sequenced from the 451 individual samples\".\n",
      "\n",
      "Rationale: The paper clearly indicates that pol gene sequences were obtained from the samples.\n",
      "\n",
      "Answer: Yes\n",
      "\n",
      "Question: 2401\n",
      "\n",
      "Evidence: The paper states that the study was conducted in Zhejiang Province, China.\n",
      "\n",
      "Rationale: The geographic region studied was Zhejiang Province in China.\n",
      "\n",
      "Answer: Zhejiang Province, China\n",
      "\n",
      "Question: 2402\n",
      "\n",
      "Evidence: The paper states that the study was conducted from 2004 to 2008.\n",
      "\n",
      "Rationale: The sequenced samples were obtained during the years 2004 to 2008.\n",
      "\n",
      "Answer: 2004 to 2008\n",
      "\n",
      "Question: 2502\n",
      "\n",
      "Evidence: The paper states that \"PCR products were purified using Qiagen gel extraction kit, and sequenced using an automated ABI 377 DNA Sequencer (Applied Biosystems).\"\n",
      "\n",
      "Rationale: This indicates that Sanger sequencing was used for the HIV-1 sequencing in this study.\n",
      "\n",
      "Answer: Yes\n",
      "\n",
      "Question: 2503\n",
      "\n",
      "Evidence: The paper does not mention the use of any next-generation sequencing (NGS) technologies.\n",
      "\n",
      "Rationale: The paper only describes the use of Sanger sequencing, and does not report the use of any NGS methods.\n",
      "\n",
      "Answer: No\n",
      "\n",
      "Question: 2504\n",
      "\n",
      "Evidence: The paper does not mention cloning of samples prior to sequencing.\n",
      "\n",
      "Rationale: There is no information provided in the paper about cloning of samples before sequencing.\n",
      "\n",
      "Answer: No\n",
      "\n",
      "Question: 2505\n",
      "\n",
      "Evidence: The paper does not mention single genome sequencing.\n",
      "\n",
      "Rationale: The paper does not report the use of single genome sequencing for the HIV-1 sequences.\n",
      "\n",
      "Answer: No\n",
      "\n",
      "Question: 2506\n",
      "\n",
      "Evidence: The paper does not mention molecular cloning of samples.\n",
      "\n",
      "Rationale: There is no information provided in the paper about molecular cloning of samples.\n",
      "\n",
      "Answer: No\n",
      "\n",
      "Question: 2601\n",
      "\n",
      "Evidence: The paper states that \"5 ml of EDTA-treated whole blood was taken from HIV-1 patient, and all samples were transferred to Zhejiang CDC in less than 12 h. The blood samples were separated into plasma and peripheral blood monocular cells (PBMC) and stored at −80 °C until use according to standard procedures.\"\n",
      "\n",
      "Rationale: This indicates that plasma samples were used for the HIV-1 sequencing.\n",
      "\n",
      "Answer: Yes\n",
      "\n",
      "Question: 2602\n",
      "\n",
      "Evidence: The paper states that the blood samples were separated into plasma and peripheral blood monocular cells (PBMC) and stored at −80 °C.\n",
      "\n",
      "Rationale: This suggests that PBMC samples were also obtained and potentially used for sequencing.\n",
      "\n",
      "Answer: Yes\n",
      "\n",
      "Question: 2603\n",
      "\n",
      "Evidence: The paper states that \"Totally, 332 *gag* and 229 *pol* gene fragments were amplified and sequenced from the 451 individual samples\".\n",
      "\n",
      "Rationale: The paper reports that 229 pol gene fragments were sequenced from the 451 samples.\n",
      "\n",
      "Answer: 229\n",
      "\n",
      "Question: 2604\n",
      "\n",
      "Evidence: The paper states that \"Totally, 332 *gag* and 229 *pol* gene fragments were amplified and sequenced from the 451 individual samples\".\n",
      "\n",
      "Rationale: The paper reports that 332 gag gene fragments were sequenced from the 451 samples.\n",
      "\n",
      "Answer: 332\n",
      "\n",
      "Question: 2605\n",
      "\n",
      "Evidence: The paper does not provide any information about whether the sequenced samples were from individuals with active HIV replication.\n",
      "\n",
      "Rationale: The paper does not specify the HIV replication status of the individuals from whom the sequenced samples were obtained.\n",
      "\n",
      "Answer: Unknown\n",
      "\n",
      "Question: 2606\n",
      "\n",
      "Evidence: The paper does not mention that the sequenced samples were obtained from the proviral DNA reservoir.\n",
      "\n",
      "Rationale: The paper indicates the samples were plasma and PBMC, but does not specify if they were from proviral DNA.\n",
      "\n",
      "Answer: No\n",
      "\n",
      "Question: 2701\n",
      "\n",
      "Evidence: The paper does not report any samples obtained from infants or children.\n",
      "\n",
      "Rationale: The paper focuses on adult HIV-1 patients in Zhejiang Province and does not mention any samples from infants or children.\n",
      "\n",
      "Answer: No\n",
      "\n",
      "Question: 2702\n",
      "\n",
      "Evidence: The paper does not indicate that any of the individuals were part of a clinical trial.\n",
      "\n",
      "Rationale: There is no mention of the individuals being part of a clinical trial in the paper.\n",
      "\n",
      "Answer: No\n",
      "\n",
      "Question: 2703\n",
      "\n",
      "Evidence: The paper does not indicate that any of the individuals were part of a clinical trial.\n",
      "\n",
      "Rationale: The paper does not provide any information about the individuals being part of a clinical trial.\n",
      "\n",
      "Answer: No\n",
      "\n",
      "Question: 3101\n",
      "\n",
      "Evidence: The paper states that \"A total of 451 HIV-1-positive patient samples were collected by local CDC staff from 2004 to 2008\".\n",
      "\n",
      "Rationale: The paper clearly states that 451 HIV-1 positive patient samples were obtained for the study.\n",
      "\n",
      "Answer: 451\n",
      "\n",
      "Question: 3102\n",
      "\n",
      "Evidence: The paper states that \"Totally, 332 *gag* and 229 *pol* gene fragments were amplified and sequenced from the 451 individual samples\".\n",
      "\n",
      "Rationale: Not all 451 samples underwent full HIV-1 sequencing, as only 332 gag and 229 pol gene fragments were sequenced.\n",
      "\n",
      "Answer: No\n",
      "\n",
      "Question: 4101\n",
      "\n",
      "Evidence: The paper does not provide any information about the ART status of the individuals whose samples were sequenced.\n",
      "\n",
      "Rationale: The paper does not report whether the sequenced samples were obtained from ART-naive individuals.\n",
      "\n",
      "Answer: Unknown\n",
      "\n",
      "Question: 4102\n",
      "\n",
      "Evidence: The paper does not provide any information about the ART status of the individuals whose samples were sequenced.\n",
      "\n",
      "Rationale: The paper does not report whether the sequenced samples were obtained from ART-experienced individuals.\n",
      "\n",
      "Answer: Unknown\n",
      "\n",
      "Question: 4103\n",
      "\n",
      "Evidence: The paper does not provide any information about the ART status of the individuals whose samples were sequenced.\n",
      "\n",
      "Rationale: The paper does not report the ART status (naive or experienced) of the individuals whose samples were sequenced.\n",
      "\n",
      "Answer: Unknown\n",
      "\n",
      "Question: 4104\n",
      "\n",
      "Evidence: The paper does not provide the number of samples obtained from ART-naive individuals.\n",
      "\n",
      "Rationale: The ART status of the individuals is not reported in the paper.\n",
      "\n",
      "Answer: Unknown\n",
      "\n",
      "Question: 4105\n",
      "\n",
      "Evidence: The paper does not provide complete ART history information for the individuals in the study.\n",
      "\n",
      "Rationale: The paper does not report any details about the ART history of the individuals whose samples were sequenced.\n",
      "\n",
      "Answer: No\n",
      "\n",
      "Question: 4201\n",
      "\n",
      "Evidence: The paper does not report any information on the prevalence of transmitted HIV drug resistance.\n",
      "\n",
      "Rationale: The paper focuses on the molecular epidemiology and subtype distribution of HIV-1 in Zhejiang province and does not include data on transmitted drug resistance.\n",
      "\n",
      "Answer: No\n",
      "\n",
      "Question: 4202\n",
      "\n",
      "Evidence: The paper does not report any information on the prevalence of pretreatment HIV drug resistance.\n",
      "\n",
      "Rationale: The paper does not provide any data on pretreatment drug resistance in the study population.\n",
      "\n",
      "Answer: No\n",
      "\n",
      "Question: 4301\n",
      "\n",
      "Evidence: The paper does not report any information about the specific antiretroviral drug classes received by the individuals in the study.\n",
      "\n",
      "Rationale: The paper does not mention the antiretroviral drug regimens taken by the study participants.\n",
      "\n",
      "Answer: Unknown\n",
      "\n",
      "Question: 4302\n",
      "\n",
      "Evidence: The paper does not report any information about individuals receiving integrase inhibitors.\n",
      "\n",
      "Rationale: The paper does not provide any details about the use of integrase inhibitors in the study population.\n",
      "\n",
      "Answer: No\n",
      "\n",
      "Question: 4303\n",
      "\n",
      "Evidence: The paper does not report any information about individuals receiving protease inhibitors.\n",
      "\n",
      "Rationale: The paper does not mention the use of protease inhibitors by the study participants.\n",
      "\n",
      "Answer: No\n",
      "\n",
      "Question: 4304\n",
      "\n",
      "Evidence: The paper does not provide any information about the antiretroviral regimens received by the individuals.\n",
      "\n",
      "Rationale: The paper does not report the antiretroviral treatments taken by the study participants.\n",
      "\n",
      "Answer: Unknown\n",
      "\n",
      "Question: 4305\n",
      "\n",
      "Evidence: The paper does not mention whether the individuals were INSTI-naive.\n",
      "\n",
      "Rationale: The paper does not provide any information about the INSTI treatment history of the study participants.\n",
      "\n",
      "Answer: Unknown\n",
      "\n",
      "Question: 4403\n",
      "\n",
      "Evidence: The paper does not report the number of individuals who received more than one ART regimen.\n",
      "\n",
      "Rationale: The paper does not include any details about the antiretroviral treatment history of the study participants.\n",
      "\n",
      "Answer: Unknown\n",
      "\n",
      "Question: 4404\n",
      "\n",
      "Evidence: The paper does not report the number of individuals who received more than two ART regimens.\n",
      "\n",
      "Rationale: The paper does not provide any information about the ART regimens received by the study participants.\n",
      "\n",
      "Answer: Unknown\n",
      "\n",
      "Question: 4405\n",
      "\n",
      "Evidence: The paper does not indicate whether all individuals received the same number of ART regimens.\n",
      "\n",
      "Rationale: The paper does not contain any details about the ART history of the study participants.\n",
      "\n",
      "Answer: Unknown\n",
      "\n",
      "Question: 4406\n",
      "\n",
      "Evidence: The paper does not specify whether all individuals received one ART regimen.\n",
      "\n",
      "Rationale: The paper does not report any information about the ART regimens received by the study participants.\n",
      "\n",
      "Answer: Unknown\n",
      "\n",
      "Question: 4501\n",
      "\n",
      "Evidence: The paper does not mention any individuals receiving dolutegravir.\n",
      "\n",
      "Rationale: The paper does not provide any information about the use of dolutegravir in the study population.\n",
      "\n",
      "Answer: 0\n",
      "\n",
      "Question: 4502\n",
      "\n",
      "Evidence: The paper does not mention any individuals receiving darunavir.\n",
      "\n",
      "Rationale: The paper does not report the use of darunavir by the study participants.\n",
      "\n",
      "Answer: 0\n",
      "\n",
      "Question: 5101\n",
      "\n",
      "Evidence: The paper does not report the number of individuals found to have one or more drug resistance mutations.\n",
      "\n",
      "Rationale: The paper does not contain any data on drug resistance mutations in the sequenced HIV-1 isolates.\n",
      "\n",
      "Answer: Unknown\n",
      "\n",
      "Question: 5102\n",
      "\n",
      "Evidence: The paper does not report the number of individuals found to have INSTI-resistance mutations.\n",
      "\n",
      "Rationale: The paper does not provide any information about INSTI-resistance mutations in the study population.\n",
      "\n",
      "Answer: Unknown\n",
      "\n",
      "Question: 5103\n",
      "\n",
      "Evidence: The paper does not report the number of individuals found to have TDF-resistance mutations.\n",
      "\n",
      "Rationale: The paper does not include data on TDF-resistance mutations in the sequenced HIV-1 isolates.\n",
      "\n",
      "Answer: Unknown\n",
      "\n",
      "Question: 5104\n",
      "\n",
      "Evidence: The paper does not mention any specific INSTI-resistance mutations that developed in the study participants.\n",
      "\n",
      "Rationale: The paper does not report any data on INSTI-resistance mutations.\n",
      "\n",
      "Answer: None\n",
      "\n",
      "Question: 6101\n",
      "\n",
      "Evidence: The paper does not report the use of any phenotypic susceptibility testing methods.\n",
      "\n",
      "Rationale: The paper does not contain any information about phenotypic susceptibility testing of the HIV-1 isolates.\n",
      "\n",
      "Answer: None\n",
      "\n",
      "Question: 6102\n",
      "\n",
      "Evidence: The paper does not report any IC values like IC50 or IC90.\n",
      "\n",
      "Rationale: The paper does not provide any data from phenotypic susceptibility assays.\n",
      "\n",
      "Answer: No\n",
      "\n",
      "Question: 6103\n",
      "\n",
      "Evidence: The paper does not report any IC50 fold change values.\n",
      "\n",
      "Rationale: The paper does not contain phenotypic susceptibility data.\n",
      "\n",
      "Answer: No\n",
      "\n",
      "Question: 6104\n",
      "\n",
      "Evidence: The paper does not mention the use of any specific phenotypic susceptibility assay.\n",
      "\n",
      "Rationale: The paper does not describe the use of phenotypic susceptibility testing.\n",
      "\n",
      "Answer: None\n",
      "\n",
      "Question: 6105\n",
      "\n",
      "Evidence: The paper does not report any data about replication capacity of the HIV-1 isolates.\n",
      "\n",
      "Rationale: The paper does not provide information on the replication capacity of the sequenced viruses.\n",
      "\n",
      "Answer: No\n",
      "\n",
      "Question: 6106\n",
      "\n",
      "Evidence: The paper does not report any data from phenotypic susceptibility testing of antiretroviral drugs.\n",
      "\n",
      "Rationale: The paper does not contain phenotypic susceptibility data for any antiretroviral drugs.\n",
      "\n",
      "Answer: None\n",
      "\n",
      "Question: 7101\n",
      "\n",
      "Evidence: The paper does not mention any site-directed mutant HIV-1 isolates.\n",
      "\n",
      "Rationale: The paper does not report the use of any site-directed mutant viruses.\n",
      "\n",
      "Answer: No\n",
      "\n",
      "Question: 7102\n",
      "\n",
      "Evidence: The paper does not indicate that any of the HIV-1 isolates resulted from in vitro passage experiments.\n",
      "\n",
      "Rationale: The paper does not describe any in vitro passage experiments performed on the HIV-1 isolates.\n",
      "\n",
      "Answer: No\n"
     ]
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b4f0634c",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "\n",
    "\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "myenv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.13"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
